Skip to Content

'
Robert L. Coleman, M.D., FACOG, FACS

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Chair, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Coleman was recruited back to the MD Anderson faculty in 2004 to help expand and coordinate the Department of Gynecologic Oncology clinical therapeutics program. Finishing the institution’s Gynecologic Oncology fellowship in 1993, he has distinguished himself as a key opinion leader in cancers of the female genital tract. He has authored and co-authored over 400 scientific publications, including over 130 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and most recently, An Atlas of Gynecologic Oncology. He is a frequently invited lecturer for national and international conferences and meetings where he continues to foster global scientific collaboration.

Before returning to MD Anderson, Dr. Coleman served as Division Director of Gynecologic Oncology at Creighton University School of Medicine and Vice-Chairman of Obstetrics and Gynecology at The University of Texas Southwestern Medical Center in Dallas. There he held the inaugural Patricia Duniven-Fletcher Professorship of Gynecologic Oncology. Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. In partnership with Departmental faculty, he has established a translational medicine pipeline, which fosters, facilitates and vets promising compounds and treatment strategies from preclinical to clinical investigation. He is the institution’s Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, as well as, numerous investigator-initiated clinical studies of novel chemotherapeutic and biological compounds in cancers of the ovary, cervix and uterus. He has also been involved in three trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-Project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, The Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. In addition, recent funding from the Cancer Prevention Research Institute of Texas (CPRIT) will be used to support a first-in-human therapeutics study of systemically delivered siRNAs in patients with solid tumors.

Dr. Coleman currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncology, the American College of Surgeons, American Association for Cancer Research and the American Society of Clinical Oncology. He also serves several International Organizations, such as the International Gynecologic Cancer Society, European Society of Gynecologic Oncology and the European Society of Medical Oncology. Dr. Coleman serves as the vice-chairman of the Department of Gynecologic Oncology Clinical Research, Director of Developmental Therapeutics and Research Administration Committees, is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee and is a Member of the Board for the Foundation for Women’s Cancer.  In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology and is a member of the M.D. Anderson Cancer Center's Center for RNA Interference and Non-Coding RNA.        

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman Pressler Drive
Unit Number: 1362
Houston, TX 77030
Room Number: CPB6.3590

Education & Training

Degree-Granting Education

1987 Creighton University School of Medicine, Omaha, NE, MD, Medicine
1983 Creighton University, Omaha, NE, BS, Mathematics

Postgraduate Training

7/1991-7/1993 Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, J. Taylor Wharton, M.D.
7/1987-7/1991 Residency, Obstetrics and Gynecology, Northwestern University Medical Center, Chicago, IL, Jack Sciarra, M.D.

Board Certifications

1/1996 American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology
1/1994 American Board of Obstetrics and Gynecology
1/1987 National Board of Medical Examiners

Experience/Service

Academic Appointments

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2004-8/2006
Associate Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/2000-7/2004
Assistant Professor, Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/1996-8/2000
Assistant Professor, Obstetrics and Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-8/1996

Other Appointments/Responsibilities

Member, The University of Texas MD Anderson Cancer Center, Center for RNA Interference and Non-Coding RNA, Houston, TX, 2009-present
Member, Board of Directors, Gynecologic Cancer Foundation, Chicago, IL, 3/2006-present
Director, Department of Obstetrics & Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-6/1996

Endowed Positions

Patricia Duniven Fletcher Professor in Gynecologic Oncology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 2/2001-7/2004

Institutional Committee Activities

Member, M. D. Anderson Conflict of Interest Committee, 9/2006-9/2011

Honors and Awards

2011 2011 Margaret Greenfield/Carmel Cohen, MD, Excellence in Ovarian Cancer Research Prize, Gynecologic Cancer Foundation

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2000-present
American Association of Cancer Researchers
Member, 1999-present
American Board of Obstetrics and Gynecology (ABOG)
Member, Division of Gynecologic Oncology, 2008-present
Examiner, Division of Gynecologic Oncology, 2006-present
Examiner, 2001-present
American College of Obstetricians and Gynecologists (ACOG)
Fellow, 1994-present
American College of Radiology Imaging Network (ACRIN), Philadelphia, PA
Member, Gynecologic Committee, 2/2010-present
American College of Surgeons (ACS),
Fellow, 1997-present
American Gynecological & Obstetrical Society (AGOS), Washington, DC
Fellow, 2007-present
American Society of Clinical Oncology (ASCO)
Member, Grants Selection Committee, 2006-present
Member, 1997-present
Association of Professors of Gynecology and Obstetrics (APGO)
Member, 1994-present
Felix Rutledge Society
Program Chairman, 2003
Member, 1993-present
Gynecologic Oncology Group (GOG)
Member, Developmental Therapeutics Committee, 12/2005-present
Institutional Principal Investigator, 8/2005-present
Institutional Co-Principal Investigator, 7/2004-8/2005
Member, Ovarian Committee, 11/2000-present
Institutional Co-Principal Investigator, 1/1990-7/2004
Gynecological Cancer Foundation
Member, Board of Directors, 2006-present
Faculty, Ovarian Cancer Survivors Courses, 2005-present
Member, Membership Committee, 1997-present
International Gynecologic Cancer Society (IGCS)
Member, IGCS 12th Annual Scientific Program Committee, 2008
Member, 2002-present
Society of Gynecologic Oncologists (SGO)
Member, Education Committee, 3/2010-3/2014
Member, Program Committee, 2006-2010
Member, Membership Committee, 1998-present
Western Association of Gynecologic Oncologists (WAGO)
Member, 1998-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol 12(12):1439-56, 6/2016. e-Pub 4/18/2016. PMID: 27087632.
2. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RC, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol 141(3):588-91, 6/2016. e-Pub 4/15/2016. PMCID: PMC4877250.
3. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. e-Pub 5/23/2016. PMID: 27217446.
4. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. e-Pub 4/27/2016. PMID: 27147567.
5. Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. e-Pub 4/3/2016. PMID: 27049967.
6. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. e-Pub 3/11/2016. PMID: 26968641.
7. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. e-Pub 3/23/2016. PMID: 27009216.
8. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Equivalency challenge: Evaluation of lipodox® as the generic equivalent for doxil® in a human ovarian cancer orthotropic mouse model. Gynecol Oncol. e-Pub 3/8/2016. PMID: 26946092.
9. Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1). Ann Oncol. e-Pub 3/30/2016. PMID: 27029706.
10. Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety. Ann Oncol. e-Pub 3/8/2016. PMID: 26961146.
11. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. e-Pub 3/3/2016. PMID: 26937753.
12. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. e-Pub 3/10/2016. PMID: 26970494.
13. Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131-143, 3/2016. e-Pub 2/3/2016. PMCID: PMC4769921.
14. Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol 140(2):193-8, 2/2016. e-Pub 11/26/2015. PMID: 26631607.
15. Coleman RL. Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol 13(2):71-2, 2/2016. e-Pub 12/31/2015. PMID: 26718108.
16. Takekuma M, Wong KK, Coleman RL. A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract 3:5, 2016. e-Pub 5/5/2016. PMCID: PMC4880811.
17. Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer. Mol Cancer Ther 14(12):2677-86, 12/2015. e-Pub 10/29/2015. PMCID: PMC4674355.
18. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 28(5):610-22, 11/9/2015. e-Pub 10/17/2015. PMCID: PMC4643364.
19. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121(19):3444-51, 10/1/2015. e-Pub 8/24/2015. PMCID: PMC4575637.
20. Slomovitz BM, Coleman RL. Reply to G. Bogani et al. J Clin Oncol 33(30):3516, 10/20/2015. e-Pub 8/3/2015. PMID: 26240222.
21. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol 9(8):1694-703, 10/2015. e-Pub 5/16/2015. PMCID: PMC4584169.
22. Bonneterre J, Hutt E, Bosq J, Graham JD, Powell MA, Leblanc E, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Gynecol Oncol 138(3):663-7, 9/2015. e-Pub 7/2/2015. PMID: 26142884.
23. Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol 138(2):267-71, 8/2015. e-Pub 5/30/2015. PMID: 26037898.
24. Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol 138(2):223-6, 8/2015. e-Pub 7/9/2015. PMID: 26166806.
25. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol 138(2):472-7, 8/2015. e-Pub 5/27/2015. PMID: 26022527.
26. Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. J Oncol Pharm Pract. e-Pub 7/15/2015. PMID: 26183293.
27. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res 21(14):3286-97, 7/15/2015. e-Pub 4/15/2015. PMCID: PMC4506247.
28. Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138(1):30-5, 7/2015. e-Pub 4/14/2015. PMCID: PMC4469526.
29. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19, 6/29/2015. e-Pub 2/7/2015. PMCID: PMC4504743.
30. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 137(3):386-91, 6/2015. e-Pub 3/24/2015. PMCID: PMC4447525.
31. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. Nat Rev Clin Oncol 12(6):358-370, 6/2015. e-Pub 3/10/2015. PMID: 25754949.
32. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137(3):553-558, 6/2015. e-Pub 3/28/2015. PMID: 25827290.
33. Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther 14(6):1466-75, 6/2015. e-Pub 4/1/2015. PMCID: PMC4458384.
34. Herzog TJ, Coleman RL, Monk BJ, Armstrong DK, Alvarez RD. In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite. J Clin Oncol 33(13):1511-2, 5/1/2015. e-Pub 3/2/2015. PMID: 25732164.
35. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol 12(4):239-245, 4/2015. e-Pub 2/24/2015. PMID: 25707631.
36. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clin Cancer Res 21(5):955-61, 3/1/2015. e-Pub 11/11/2014. PMCID: PMC4333206.
37. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. J Clin Oncol 33(8):930-6, 3/10/2015. e-Pub 1/26/2015. PMCID: PMC4348638.
38. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev 34(1):19-40, 3/2015. e-Pub 12/30/2014. PMCID: PMC4369424.
39. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 34(1):41-52, 3/2015. e-Pub 1/7/2015. PMID: 25564455.
40. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol 27(1):58-65, 2/2015. PMID: 25502429.
41. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21(2):448-59, 1/15/2015. e-Pub 11/21/2014. PMCID: PMC4297546.
42. Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecol Oncol 136(1):94-8, 1/2015. e-Pub 11/25/2014. PMID: 25462203.
43. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5(22):11168-79, 11/30/2014. e-Pub 10/29/2014. PMCID: PMC4294378.
44. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm. Gynecol Oncol 135(1):3-7, 10/2014. e-Pub 8/12/2014. PMID: 25124162.
45. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer 111(5):843-50, 8/26/2014. e-Pub 7/8/2014. PMCID: PMC4150278.
46. Wolfe LM, Thiagarajan RD, Boscolo F, Taché V, Coleman RL, Kim J, Kwan WK, Loring JF, Parast M, Laurent LC. Banking placental tissue: an optimized collection procedure for genome-wide analysis of nucleic acids. Placenta 35(8):645-54, 8/2014. e-Pub 6/6/2014. PMID: 24951174.
47. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26(1):77-91, 7/14/2014. PMCID: PMC4100212.
48. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(8):799-808, 7/2014. e-Pub 6/17/2014. PMID: 24950985.
49. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 15(7):919-29, 7/2014. e-Pub 4/23/2014. PMCID: PMC4100993.
50. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: Emerging therapies in gynecologic cancer. Gynecol Oncol 134(1):6-9, 7/2014. PMID: 24952408.
51. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20(12):3280-8, 6/15/2014. e-Pub 4/22/2014. PMCID: PMC4062703.
52. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 Pathway Alterations in Ovarian Cancer. Cancer Res 74(12):3282-93, 6/15/2014. e-Pub 4/17/2014. PMCID: PMC4058356.
53. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50(9):1638-48, 6/2014. e-Pub 4/4/2014. PMCID: PMC4098779.
54. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biological effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clin Cancer Res 20(10):2740-50, 5/15/2014. e-Pub 3/14/2014. PMCID: PMC4024372.
55. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer. Int J Gynecol Cancer 24(4):713-7, 5/2014. e-Pub 3/19/2014. PMCID: PMC4039301.
56. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 4/24/2014. e-Pub 4/3/2014. PMCID: PMC4038960.
57. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib. Clin Cancer Res 20(7):1846-55, 4/1/2014. e-Pub 1/31/2014. PMCID: PMC3975695.
58. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of (18)F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol 133(1):100-4, 4/2014. e-Pub 2/15/2014. PMCID: PMC4000233.
59. Graybill WS, Coleman RL. Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol 10(4):541-8, 3/2014. PMID: 24754586.
60. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 132(1):8-17, 1/2014. e-Pub 11/15/2013. PMID: 24239753.
61. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 132(1):166-75, 1/2014. e-Pub 10/29/2013. PMCID: PMC3946949.
62. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 31(35):4400-6, 12/10/2013. e-Pub 10/14/2013. PMID: 24127448.
63. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting Src and tubulin in mucinous ovarian carcinoma. Clin Cancer Res 19(23):6532-43, 12/1/2013. e-Pub 10/7/2013. PMCID: PMC3852199.
64. Galic V, Coleman RL, Herzog TJ. Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways. Curr Cancer Drug Targets 13(6):698-707, 7/2013. e-Pub 5/6/2013. PMID: 23675882.
65. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129(3):452-8, 6/2013. e-Pub 3/6/2013. PMID: 23474348.
66. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10(4):211-24, 4/2013. e-Pub 2/5/2013. PMCID: PMC3786558.
67. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 128(3):506-11, 3/2013. e-Pub 11/28/2012. PMCID: PMC3645276.
68. Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther 13(2):283-94, 2/2013. e-Pub 11/29/2012. PMCID: PMC3799801.
69. Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA. Evaluation of Pegylated Liposomal Doxorubicin Dose on the Adverse Drug Event Profile and Outcomes in Treatment of Recurrent Endometrial Cancer. Int J Gynecol Cancer 23(2):348-354, 2/2013. PMCID: PMC3899886.
70. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 31(1):213-29, 2/2013. e-Pub 6/4/2012. PMCID: PMC4103697.
71. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol 128(2):155-9, 2/2013. e-Pub 11/29/2012. PMCID: PMC3638213.
72. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31(1):77-84, 2/2013. e-Pub 2/28/2012. PMCID: PMC3553417.
73. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14(2):134-40, 2/2013. e-Pub 12/21/2012. PMID: 23261356.
74. Schmeler KM, Wilson GL, Cain K, Munsell MF, Ramirez PT, Soliman PT, Nick AM, Frumovitz M, Coleman RL, Kroll MH, Levenback CF. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol 128(2):204-8, 2/2013. e-Pub 11/28/2012. PMCID: PMC3826112.
75. Craig CD, Iglesias DA, Watkins J, Coleman RL, Kilgore L, Ramirez PT. Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. Gynecol Oncol Case Rep 5:64-66, 2013. e-Pub 5/19/2013. PMCID: PMC3862230.
76. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 127(3):538-43, 12/2012. e-Pub 8/23/2012. PMCID: PMC3568489.
77. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. J Clin Oncol 30(31):3786-91, 11/1/2012. e-Pub 7/2/2012. PMCID: PMC3478573.
78. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies. J Clin Oncol 30(32):4026-34, 11/10/2012. e-Pub 9/24/2012. PMCID: PMC3488272.
79. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer. Clin Cancer Res 18(21):5856-64, 11/1/2012. e-Pub 10/18/2012. PMID: 23082003.
80. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 7/2012. e-Pub 4/6/2012. PMCID: PMC3738300.
81. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study. Cancer 118(12):3087-94, 6/15/2012. e-Pub 11/9/2011. PMID: 22072418.
82. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125(3):640-5, 6/2012. e-Pub 2/28/2012. PMID: 22387451.
83. Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am 26(3):543-63, viii, 6/2012. PMCID: PMC3334841.
84. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol 125(1):5-7, 4/2012. e-Pub 12/28/2011. PMCID: PMC3746346.
85. Nihira MA, Drake NL, Corton MM, Wai CY, Coleman RL, Quiroz LH. Reported Cystoscopic Experience Correlates Poorly With Objective Assessment of Cystoscopic Skills. Female Pelvic Med Reconstr Surg 18(2):97-102, Mar-Apr, 3/2012. PMID: 22453320.
86. Sood AK, Coleman RL, Ellis LM. Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer. J Clin Oncol 30(4):345-7, 2/1/2012. e-Pub 12/19/2011. PMID: 22184398.
87. Julius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA. Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. J Antimicrob Chemother 67(2):422-9, 2/2012. e-Pub 11/30/2011. PMID: 22129592.
88. Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL, Gynecologic Oncology Group. Nodal Metastasis Risk in Endometrioid Endometrial Cancer. Obstet Gynecol 119(2, Part 1):286-292, 2/2012. PMCID: PMC3266531.
89. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer. Curr Pharm Des 18(19):2713-9, 2012. e-Pub 2/28/2012. PMCID: PMC3740204.
90. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. Clin Cancer Res 17(21):6840-6, 11/1/2011. e-Pub 9/2/2011. PMCID: PMC3207033.
91. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103(21):1596-612, 11/2/2011. e-Pub 9/28/2011. PMCID: PMC3206039.
92. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12(12):1109-17, 11/2011. e-Pub 10/10/2011. PMCID: PMC3444811.
93. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the delta family notch ligand dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71(18):6030-9, 9/15/2011. e-Pub 7/27/2011. PMCID: PMC3174342.
94. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res 17(17):5674-85, 9/1/2011. e-Pub 7/13/2011. PMCID: PMC3166981.
95. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71(11):1397-412, 7/30/2011. PMID: 21812505.
96. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 122(1):111-5, 7/2011. e-Pub 4/15/2011. PMCID: PMC3104117.
97. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN. Preoperative Factors Predicting Survival After Secondary Cytoreduction for Recurrent Ovarian Cancer. Int J Gynecol Cancer 21(5):831-6, 7/2011. e-Pub 5/18/2011. PMID: 21613957.
98. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 121(2):264-8, 5/1/2011. e-Pub 2/1/2011. PMCID: PMC3081997.
99. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928-34, 5/1/2011. e-Pub 11/16/2010. PMCID: PMC4286384.
100. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecol Oncol 121(2):303-8, 5/1/2011. e-Pub 2/16/2011. PMCID: PMC3081894.
101. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 121(2):323-7, 5/1/2011. e-Pub 1/28/2011. PMID: 21277011.
102. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 4/15/2011. e-Pub 11/8/2010. PMCID: PMC3062960.
103. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma. Int J Gynecol Cancer 21(3):517-22, 4/2011. PMID: 21436700.
104. Armstrong DK, Coleman RL, Penson RT. Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol 9(4 Suppl 5):1-16, 4/2011. PMID: 21558997.
105. Slomovitz BM, Worley MJ, Markman M, Coleman RL. Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs 16(1):71-84, 3/2011. PMID: 21352070.
106. Ito K, Tsubamoto H, Itani Y, Kuroboshi H, Fujita H, Nobunaga T, Coleman RL. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: A Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol 120(2):193-7, 2/2011. e-Pub 12/22/2010. PMID: 21075434.
107. Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, Ramirez PT. Neoadjuvant Chemotherapy is Associated with Prolonged Primary Treatment Intervals in Patients with Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer 21(1):66-71, 1/2011. PMID: 21178571.
108. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59-67, 1/2011. e-Pub 12/16/2010. PMCID: PMC3199132.
109. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed) 3:82-97, 2011. e-Pub 1/1/2011. PMCID: PMC3199127.
110. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23):5415-9, 12/1/2010. e-Pub 8/2/2010. PMID: 20681032.
111. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 10(12):1306-14, 12/15/2010. e-Pub 12/15/2010. PMCID: PMC3047089.
112. Zand B, Euscher ED, Soliman PT, Schmeler KM, Coleman RL, Frumovitz M, Jhingran A, Ramondetta LM, Ramirez PT. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol 119(3):422-5, 12/2010. e-Pub 9/15/2010. PMCID: PMC4286254.
113. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12):3186-99, 12/2010. e-Pub 10/1/2010. PMCID: PMC3005138.
114. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 116(21):4973-9, 11/1/2010. e-Pub 7/21/2010. PMCID: PMC4210375.
115. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. e-Pub 11/16/2010. PMID: 21082702.
116. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. e-Pub 11/8/2010. PMID: 21061326.
117. Smith AL, Frumovitz M, Schmeler KM, dos Reis R, Nick AM, Coleman RL, Ramirez PT. Conservative surgery in early-stage cervical cancer: What percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol 119(2):183-6, 11/2010. e-Pub 8/12/2010. PMCID: PMC4286388.
118. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer 20(7):1290-8, 10/2010. PMCID: PMC2998994.
119. Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol 116(4):956-61, 10/2010. PMID: 20859161.
120. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 8/9/2010. PMCID: PMC2923653.
121. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 8/2010. e-Pub 8/3/2010. PMCID: PMC2933364.
122. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 203(1):68.e1-6, 7/2010. e-Pub 3/12/2010. PMID: 20227055.
123. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 6/2010. e-Pub 3/26/2010. PMCID: PMC2882061.
124. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16(9):2562-70, 5/1/2010. e-Pub 4/13/2010. PMCID: PMC3955167.
125. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 11(5):465-75, 5/2010. e-Pub 3/10/2010. PMCID: PMC3199129.
126. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116(8):1918-25, 4/15/2010. e-Pub 2/17/2010. PMCID: PMC2854845.
127. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95, 4/2010. e-Pub 4/6/2010. PMCID: PMC2852465.
128. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10(3):431-7, 3/2010. e-Pub 1/2010. PMID: 20092424.
129. Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol 116(2):155-6, 2/2010. PMID: 20109724.
130. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176-82, 2/2010. e-Pub 2/16/2010. PMCID: PMC3155813.
131. Monk BJ, Coleman RL. Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds. Int J Gynecol Cancer 19 Suppl 2:S63-7, 12/2009. PMID: 19955917.
132. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer. Cancer Biol Ther 8(23):2263-72, 12/2009. e-Pub 12/19/2009. PMID: 19829059.
133. Coleman RL. Emergence of truly "individualized" therapy: the poly (adenosine diphosphate-ribose) polymerase inhibitors. Curr Oncol Rep 11(6):414-6, 11/2009. PMID: 19840517.
134. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 374(9698):1371-82, 10/2009. e-Pub 9/2009. PMID: 19793610.
135. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. J Natl Cancer Inst 101(17):1193-205, 9/2/2009. e-Pub 7/29/2009. PMCID: PMC2736292.
136. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431-6, 9/2009. e-Pub 6/13/2009. PMID: 19524286.
137. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-603, 8/2009. e-Pub 8/13/2009. PMID: 19738426.
138. Levenback CF, van der Zee AG, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol 114(2):151-6, 8/2009. PMID: 19457548.
139. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 7/2009. e-Pub 4/10/2009. PMID: 19361839.
140. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115(12):2684-92, 6/15/2009. e-Pub 4/24/2009. PMID: 19396818.
141. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMCID: PMC2752981.
142. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol 5(5):591-600, 6/2009. PMCID: PMC2744352.
143. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual Targeting of EphA2 and FAK in Ovarian Carcinoma. Cancer Biol Ther 8(11):1123-30, 6/2009. e-Pub 6/24/2009. PMCID: PMC2748749.
144. Santoso JT, Azadi A, Wan J, Handorf C, Coleman RL, Tillmanns TD. Lymph node counts in uterine cancer: A randomized double blind trial. Gynecol Oncol 113(2):159-62, 5/2009. e-Pub 3/5/2009. PMID: 19268343.
145. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124(5):1045-1053, 3/1/2009. e-Pub 9/2008. PMCID: PMC2668132.
146. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J 15(2):176-81, Mar-Apr, 3/2009. PMID: 19292804.
147. Kamat AA, Coleman RL. Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox. Cancer Biol Ther 8(1):18-20, 1/2009. e-Pub 1/29/2009. PMID: 19127119.
148. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. N Engl J Med 359(25):2641-2650, 12/18/2008. PMCID: PMC2710981.
149. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 111(3):467-73, 12/2008. e-Pub 10/1/2008. PMID: 18834619.
150. Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT. Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol 15(6):723-8, Nov-Dec, 11/2008. PMID: 18971136.
151. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 9/1/2008. PMCID: PMC2766914.
152. Coleman RL. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials. Gynecol Oncol 110(3S2):S77-S80, 9/2008. e-Pub 6/2008. PMID: 18584855.
153. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 7/15/2008. PMCID: PMC2547344.
154. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 110(1):56-9, 7/2008. e-Pub 5/5/2008. PMID: 18457865.
155. Ramirez PT, Frumovitz M, Dos Reis R, Milam MR, Bevers MW, Levenback CF, Coleman RL. Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer 18(3):571-5, May-Jun, 5/2008. e-Pub 8/10/2007. PMID: 17692091.
156. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5(4):194-204, 4/2008. e-Pub 2/2008. PMID: 18268546.
157. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on anti-angiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477.e1-9, 4/2008. PMCID: PMC2346589.
158. Isonishi S, Coleman RL, Hirama M, Iida Y, Kitai S, Nagase M, Ochiai K. Analysis of Prognostic Factors for Patients with Leiomyoma treated with Uterine Arterial Embolization. Am J Obstet Gynecol 198(3):270.e1-6, 3/2008. e-Pub 11/12/2007. PMID: 17997392.
159. Frumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol 108(3):478-81, 3/2008. e-Pub 1/10/2008. PMID: 18190952.
160. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 3/2008. e-Pub 12/26/2007. PMID: 18155273.
161. Ramirez PT, Landen CN, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM. Phase I Trial of the Proteasome Inhibitor Bortezomib in Combination with Carboplatin in Patients with Platinum- and Taxane-Resistant Ovarian Cancer. Gynecol Oncol 108(1):68-71, 1/2008. e-Pub 10/1/2007. PMID: 17905421.
162. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ 23(4):235-7, 2008. PMID: 19058072.
163. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT. Adenosquamous Carcinoma versus Adenocarcinoma in Early-Stage Cervical Cancer Patients Undergoing Radical Hysterectomy: An Outcomes Analysis. Gynecol Oncol 107(3):458-63, 12/2007. e-Pub 9/2007. PMID: 17854872.
164. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13(24):7487-95, 12/2007. PMID: 18094433.
165. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67(19):9337-45, 10/2007. PMID: 17909042.
166. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman RL, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 106(2):375-80, 8/2007. e-Pub 5/2007. PMID: 17512575.
167. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13(14):4209-17, 7/2007. PMID: 17634550.
168. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 5/2007. e-Pub 2/9/2007. PMID: 17292461.
169. Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 13(1):39-45, 3/2007. PMID: 17621566.
170. Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 109(3):641-6, 3/2007. PMID: 17329515.
171. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2/2007. PMID: 17308118.
172. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-8, 1/1/2007. PMID: 17210709.
173. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12(1):72-8, 1/2007. PMID: 17227902.
174. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther 5:1708-13, 12/2006. PMID: 17106249.
175. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol 105(1):7-12, 12/2006. e-Pub 12/20/2006. PMID: 17187847.
176. Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep 8:455-64, 11/2006. PMID: 17040624.
177. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ.. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 103:212-8, 10/2006. PMID: 16677696.
178. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66(17):8633-9, 9/2006. PMID: 16951177.
179. Slomovitz BM, Ramirez PT, Frumovitz M, Soliman PT, Bevers M, Coleman RL, Levenback C. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol 102(3):534-6, 9/2006. PMID: 16483643.
180. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol 104(1):100-3, 9/2006. e-Pub 9/11/2006. PMID: 16963111.
181. Herzog TJ, Coleman RL, Guerrieri JP, Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol 195(2):445-53, 8/2006. PMID: 16626607.
182. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939-44, 8/2006. PMID: 16862152.
183. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 8/2006. PMID: 16880307.
184. Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12(16):4916-24, 8/2006. PMID: 16914580.
185. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol 102(2):218-25, 8/2006. PMID: 16460787.
186. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C. Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol 102(2):252-5, 8/2006. PMID: 16472844.
187. Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol 103:888-90, 6/2006. PMID: 16806436.
188. Rao GG, Kurien A, Gossett D, Griffith WF, Coleman RL, Muller CY. A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol 101(2):250-4, 5/2006. PMID: 16297972.
189. Coleman RL, Frumovitz M, Levenback CF. Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix. J Natl Compr Canc Netw 4(5):471-8, 5/2006. PMID: 16687095.
190. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1):126-31, 4/2006. PMID: 16271384.
191. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Gershenson DM, Levenback CF. Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol 194(4):1186-93; discussion 1193-5, 4/2006. PMID: 16580331.
192. Coleman NM, Smith-Zagone MJ, Tanyi J, Anderson ML, Coleman RL, Dyson SW, Reed JA. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am J Surg Pathol 30(3):405-10, 3/2006. PMID: 16538063.
193. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16:194-201, 1/2006. PMID: 16445633.
194. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 97(1):10-5, 4/2005. PMID: 15790431.
195. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 96(1):168-72, 2005. PMID: 15589596.
196. Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 95(3):564-9, 12/2004. PMID: 15581964.
197. Moschos E, Coleman RL. Acquiring laparoscopic skill proficiency: does orientation matter? Am J Obstet Gynecol 191(5):1782-7, 11/2004. PMID: 15547564.
198. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95(2):273-80, 11/2004. PMID: 15491746.
199. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94(2):320-4, 8/2004. PMID: 15297168.
200. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 104(2):261-6, 8/2004. PMID: 15291997.
201. Delin JB, Miller DS, Coleman RL. Other primary malignancies in patients with uterine corpus malignancy. Am J Obstet Gynecol 190(5):1429-31, 5/2004. PMID: 15167859.
202. Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 190(3):674-9, 3/2004. PMID: 15041998.
203. Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 190(3):668-73, 3/2004. PMID: 15041997.
204. Santoso JT, Cannada T, O'Farrel B, Alladi K, Coleman RL. Subjective versus objective nutritional assessment study in women with gynecological cancer: a prospective cohort trial. Int J Gynecol Cancer 14(2):220-3, 3/2004. PMID: 15086719.
205. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor board in gynecologic oncology. Int J Gynecol Cancer 14(2):206-9, 3/2004. PMID: 15086716.
206. Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol 91(3):558-62, 12/2003. PMID: 14675676.
207. Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS. Management of low-risk gestational trophoblastic neoplasia in indigent women. J Reprod Med 48(10):780-4, 10/2003. PMID: 14628732.
208. Corton MM, Wai CY, Vakili B, Boreham MK, Schaffer JI, Coleman RL. A comprehensive pelvic dissection course improves obstetrics and gynecology resident proficiency in surgical anatomy. Am J Obstet Gynecol 189(3):647-51, 9/2003. PMID: 14526284.
209. Santoso JT, Lucci JA, 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52(1):13-8, 7/2003. PMID: 12719883.
210. Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL. Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study. Am J Obstet Gynecol 188(3):640-4, 3/2003. PMID: 12634634.
211. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. J Biomed Biotechnol 2003(5):308-314, 2003. PMID: 14688417.
212. Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 87(1):129-32, 10/2002. PMID: 12468353.
213. Muller CY, Coleman RL, Toler K, Gibbons D, Ashfaq R, Voet RL. Adequacy of oophorectomy at the time of gynecologic surgery. Int J Gynaecol Obstet 77(1):23-9, 4/2002. PMID: 11929652.
214. Coleman RL, Muller CY. Effects of a laboratory-based skills curriculum on laparoscopic proficiency: a randomized trial. Am J Obstet Gynecol 186(4):836-42, 4/2002. PMID: 11967517.
215. Coleman RL, Mahoney NM, Hatch KD. Laparoscopic management of urolithiasis in a continent urostomy. Gynecol Oncol 84(3):473-8, 3/2002. PMID: 11855892.
216. Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO. Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection. Gynecol Oncol 84(2):285-8, 2/2002. PMID: 11812088.
217. Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol 20(3):688-93, 2/2002. PMID: 11821449.
218. Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 7 Suppl 5:46-55, 2002. PMID: 12324633.
219. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 84(1):115-9, 2002. PMID: 11748986.
220. Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol 83(2):383-7, 11/2001. PMID: 11606101.
221. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 83(2):276-81, 11/2001. PMID: 11606084.
222. O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study. Gynecol Oncol 79(2):238-43, 11/2000. PMID: 11063651.
223. Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL. Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. Obstet Gynecol 96(1):23-7, 7/2000. PMID: 10862836.
224. Muller CY, Coleman RL, Adams WP, Jr. Laparoscopy in patients following transverse rectus abdominis myocutaneous flap reconstruction. Obstet Gynecol 96(1):132-5, 7/2000. PMID: 10928902.
225. Santoso JT, Canada T, Latson B, Aaaadi K, Lucci JA, 3rd, Coleman RL. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet Gynecol 95(6 Pt 1):844-6, 6/2000. PMID: 10831978.
226. Coleman RL Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol 1(2):177-90, 6/2000. PMID: 12057056.
227. Lin WM, Michalopulos EA, Dhurander N, Cheng PC, Robinson W, Ashfaq R, Coleman RL, Muller CY. Allelic loss and microsatellite alterations of chromosome 3p14.2 are more frequent in recurrent cervical dysplasias. Clin Cancer Res 6(4):1410-4, 4/2000. PMID: 10778971.
228. Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A. Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report. Int J Gynecol Pathol 19(2):179-82, 4/2000. PMID: 10782417.
229. Hameed A, Coleman RL. . Fine-needle aspiration cytology of primary granulosa cell tumor of the adrenal gland: a case report. Diagn Cytopathol 22:107-9, 2/2000. PMID: 10649522.
230. von Gruenigen VE, Coleman RL, King MR, Miller DS. Abdominal compartment syndrome in gynecologic surgery. Obstet Gynecol 94(5 Pt 2):830-2, 11/1999. PMID: 10546746.
231. Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J. Frequent expression of beta-human chorionic gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix. Int J Gynecol Pathol 18(4):381-6, 10/1999. PMID: 10542948.
232. Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int J Gynecol Cancer 9(5):365-372, 9/1999. PMID: 11240795.
233. Coleman RL, Whitten CW, O'Boyle J, Sidhu B. Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of Lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. J Surg Oncol 70(2):126-9, 2/1999. PMID: 10084657.
234. Santoso JT, Lucci JA, 3rd, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM. Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix? Gynecol Oncol 71(3):359-63, 12/1998. PMID: 9887231.
235. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 69(3):197-204, 6/1998. PMID: 9648587.
236. Santoso JT, Coleman RL, Voet RL, Bernstein SG, Lifshitz S, Miller D. Pathology slide review in gynecologic oncology. Obstet Gynecol 91(5 Pt 1):730-4, 5/1998. PMID: 9572220.
237. Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Semin Oncol 24(6 Suppl 20):S20-55-S20-63, 12/1997. PMID: 9425962.
238. Coleman RL, Bagnell KG, Townley PM. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma. Cancer J Sci Am 3(4):246-53, 7/1997. PMID: 9263631.
239. Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 57(2):215-20, 5/1995. PMID: 7729737.
240. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 55(1):29-35, 10/1994. PMID: 7959262.
241. Lynch HT, Lynch J, Conway T, Watson P, Coleman RL. Familial aggregation of carcinoma of the endometrium. Am J Obstet Gynecol 171(1):24-7, 7/1994. PMID: 8030707.
242. Coleman RL, Burke TW, Morris M, Eifel PJ, Hallum AV, 3rd, Wallace S, Tornos C. Intraoperative radiographs to confirm the adequacy of lymph node resection in patients with suspicious lymphangiograms. Gynecol Oncol 51(3):362-7, 12/1993. PMID: 8112646.
243. Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol 50:20-4, 7/1993. PMID: 8349159.

Invited Articles

1. Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol 141(1):1, 4/2016. PMID: 27016221.
2. Coleman RL. Two-step Screening for Ovarian Cancer: A 'Scissor-step' Froward? Commentary On: "A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predicitve value. Lu KH, et al. Cancer 2013: Epub ahead of print.". OB/GYN Clinical Alert 30(6):41-48, 10/2013.
3. Coleman RL. What is the Impact of Pediatric Cancer Care on Future Fertility in Female Survivors? Commentary on: 'Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study cohort. Barton SE, et al. Lancet Oncol 2013; ePub ahead of print Jul 12". OB/GYN Clinical Alert 30(5):33-40, 9/2013.
4. Coleman RL. PAP 3.0-The Next Generation, Commentary on: "Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Kinde I, et al. Sco Transl Med. 2013; 5:167ra4". OB/GYN Clinical Alert 30(4), 8/2013.
5. Coleman RL. Targeted Therapy for LGSOC Shows Promise, Commentary on: "Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study. Farley J, et al. Lancet Oncol. 2013; 14:134-140". OB/GYN Clinical Alert 30(3), 7/2013.
6. Coleman RL. The Right Care, the Right Time, the Right Doc: Only Part of The Story..Commentary on "Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. Bristow RE, et al. J Natl Cancer Inst 2013; Apr 4 E pub.". OB/GYN Clinical Alert 30(2):916, 6/2013.
7. Coleman RL. Laparoscopy vs Laparotomy in Early Uterine Cancer: We Still Don't Know: Commentary on "Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: A Gynecologic Oncology Group LAP2 study. Walker JL, et al. J Clin Oncol 2012; 30:695-700.". OB/GYN Clinical Alert 29(12):89-96, 4/2013.
8. Coleman RL. "Off-target" Effects? The Role of Statins in Cancer Biology: Commentary on "Statin use and reduced cancer related mortality. Nielsen SF, et al. N Engl J med 2012; 367:1792-1802.". OB/GYN Clinical Alert 29(11):81-88, 3/2013.
9. Coleman RL. Special Feature: Quality of Care in Ovarian Cancer. OB/GYN Clincal Alert 29(9):65-72, 1/2013.
10. Coleman RL. Clinical Considerations for Uterine Serous Cancer: Commentary on " Prognostic determinants in patients with stage 1 uterine papillary serous carcinoma: A 15-year multi-institutional review. Growdon WB, et al. Int J Gyne col Cancer 2012; 22:417-424.". OB/GYN Clinical Alert 29(8):57-64, 12/2012.
11. Coleman RL. Special Feature: Stress and Poor Cancer Outcomes: It's More Than Psychological. OB/GYN Clinical Alert 29(7):49-56, 11/2012.
12. Coleman RL. The Changing Paradigm of Vulva Cancer Management: Commentary on "Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: A Gynecologic Oncology Group Study. Levenback CF, et al. J Clin Oncol 2012; 29:41-48.". OB/GYN Clinical Alert 29(6):41-48, 10/2012.
13. Coleman RL. Endometriosis Implicated Again in Histological Variants of Ovarian Cancer: Commentary on "Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Pearce Cl, et al. Lancet Oncol 2012;13:385-394. OB/GYN Clinical Alert 29(5):33-40, 9/2012.
14. Coleman RL. PARP Inhibitor Maintenance SCORES in Ovarian Cancer: Commentary on, "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. Ledermann J, et al. 2012;366:1382-1392.". OB/GYN Clinical Alert 29(4):25-32, 8/2012.
15. Coleman RL. Special Feature: Robotics in Gynecologic Oncology Surgery: Justified or Just Great Marketing? OB/GYN Clinical Alert 29(2):9-16, 6/2012.
16. Coleman RL. Sentinel-Node Biopsy in Endometrial Cancer: Valid Approach? Commentary on "Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: A prospective multicentre study (SENTI-ENDO). Ballester M, et al. Lancet Oncol 2011;12:469-476.". OB/GYN Clinical Alert 29(1):1-8, 5/2012.
17. Coleman RL. Platelets and Cancer: Friend or Foe? Commentary on "Paraneoplastic thrombocytosis in ovarian cancer. Stone RL, et al. New Engl J Med 2012;366:610-618.". OB/GYN Clinical Alert 28(12):89-96, 4/2012.
18. Coleman, RL. Prognostic and Practical Implications of Germline BRCA Status. Commentary on "Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Bolton KL, et al. JAMA 2012;307:382-390.". Ob/Gyn Clincal Alert 28(11):81-88, 3/2012.
19. Coleman RL. Do We Have a New Standard of Care for Advanced Ovarian Cancer? Commentary on, "Incorporation of bevacizumab in the primary treatment of ovarian cancer. Burger RA, et al. N Engl J Med 2011;365:2473-2483.". OB/GYN Clinical Alert 28(10):73-80, 2/2012.
20. Coleman, RL. VTE Prophylaxis in Gynecologic Surgery: Quo Vadis? Commentary on, "Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery. Wright JD, et al. Obstet Gynecol 2011;118:978-986.". Ob/Gyn Clinical Alert 28(8):57-64, 12/2011.
21. Coleman, RL. The Rapalogs: New Class of Therapy for Women with Endometrial Cancer. Commentary on, "Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. Oza AM, et al. J Clin Oncol 2011;29:3278-3285.". Ob/Gyn Clinical Alert 28(7):52-53, 11/2011.
22. Coleman, RL. Are Ovarian Inclusion Cysts a Precursor for Ovarian Cancer in Menopausal Women? Commentary on, "Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A prospective cohort study. Sharma A, et al. BJOG 2011.". Ob/Gyn Clinical Alert 28(6):41-42, 10/2011.
23. Coleman, RL. Screening for Ovarian Cancer: Could it Cause More Harm than Good? Commentary on, "Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. Buys SS, et al. JAMA 2011; 305: 2295-2303.". Ob/Gyn Clinical Alert 28(5):36-38, 9/2011.
24. Coleman, RL. Is it Time to Change the Standard of Care for Low-risk GTN? Commentary on, "Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study. Osborne RJ, et al. J Clin Oncol 2011; 29:825-831.". Ob/Gyn Clinical Alert 28(4):30-32, 8/2011.
25. Coleman, RL. Is There Negative Impact from Morcellation in Unsuspected Leiomyosarcoma? Commentary on, "The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Park JY, et al. Gynecol Oncol 2011, doi:10.1016/j.ygynon.2011.04.021.". Ob/Gyn Clinical Alert 28(3):21-22, 7/2011.
26. Coleman, RL. Special Feature: Is it Heresy or Good Medicine? HRT in Survivors of Gynecological Malignancies. Ob/Gyn Clinical Alert 28(2):13-16, 6/2011.
27. Coleman, RL. Endometriosis-Associated Ovarian Cancer: Poor Clinical Reputation? Commentary on, "Prognostic analysis of ovarian cancer associated with endometriosis. Kumar S, et al. Am J Obstet Gynecol 2011;204:63.e1-7.". Ob/Gyn Clinical Alert 28(1):1-4, 5/2011.
28. Coleman, RL. HPV Vaccination in Males: Is There Value? Commentary on, "Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. Giuliano AR, et al. New Eng J Med 2011;364:401-411.". Ob/Gyn Clinical Alert 27(12):93-94, 4/2011.
29. Coleman, RL. A New Clinical Entity for Ovarian Cancer. Commentary on, "Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: Outcomes in the partially platinum-sensitve (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Poveda A, et al. Ann Oncol 2011;22:39-48. Ob/Gyn Clinical Alert 27(11):83-84, 3/2011.
30. Coleman, RL. Will Ovarian Cancer Screening Really Impact Mortality? Commentary on, "Development of an ovarian cancer screening decision model that incorporates disease heterogenity. Havrilesky, et al. Cancer 2011;117:545-553.". Ob/Gyn Clinical Alert 27(11):84-85, 3/2011.
31. Coleman, RL. Complications of Products Developed to Prevent Complications. Commentary on, "Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Krill LS, et al. Gynecol Oncol 2010 Dec 7; Epub ahead of print.". Ob/Gyn Clinical Alert 27(10):79-80, 2/2011.
32. Coleman, RL. Special Feature: Primary Ovarian Surgical Cytoreduction: When? How Much? Why? Ob/Gyn Clinical Alert 27(9):69-72, 1/2011.
33. Coleman, RL. Early Detection and Treatment of Ovarian Cancer Improves Outcome: Right? Commentary on, "Early vs delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Rustin GJS, et al. Lancet 2010;376:1155-1163.". Ob/Gyn Clinical Alert 27(8):62-63, 12/2010.
34. Coleman RL. Maximal Cytoreduction May Be of Merit in Advanced/Recurrent Endometrial Cancer. Commentary on, "Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis. Barlin JN, et al. Gynecol Oncol 2010;118:14-18.". Ob/Gyn Clinical Alert 27(7):55-56, 11/2010.
35. Coleman RL. New Biological Agents for the Treatment of Cervical Cancer. Commentary on, "Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therarpy in patients with advanced and recurrent cervical cancer. Monk BJ, et al. J Clin Oncol 2010;28:3562-3569.". Ob/Gyn Clinical Alert 27(6):45-46, 10/2010.
36. Coleman RL. Paclitaxel and Carboplatin: A Relevant Combination in Uterine Carcinosarcoma. Commentary on, "Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Powel MA, et al. J Clin Oncol 2010; 28:2727-2731.". Ob/Gyn Clinical Alert 27(5):36-37, 9/2010.
37. Coleman RL. BRCAness Correlates with Chemotherapy Responsiveness and Clinical Outcome in Ovarian Cancer. Commentary on, "Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Konstantinopoulos PA, et al. J Clin Oncol 2010 June 14; Epub ahead of print.". Ob/Gyn Clinical Alert 27(4):28-29, 8/2010.
38. Coleman RL. Adding Another Standard to Platinum-sensitive Recurrent Ovarian Cancer. Commentary on, "Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Pujade-Lauraine E, et al. J Clin Oncol 2010 May 24; Epub ahead of print.". Ob/Gyn Clinical Alert 27(3):22-23, 7/2010.
39. Coleman RL. Special Feature: BRCA1/2 Mutations: Missed Opportunities. Ob/Gyn Clinical Alert 27(2):14-16, 6/2010.
40. Coleman RL. Fertility-sparing Surgery in Ovarian Cancer: Is it Safe? Commentary on, "Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: A proposal for patient selection. Satoh T, et al. J Clin Oncol 2010;28:1727-1732.". Ob/Gyn Clinical Alert 27(1):3-4, 5/2010.
41. Coleman RL. Nodal Resection in Ovarian Cancer: Does It Matter? Commentary on, "Potential role of lymphadenectomy in advanced ovarian cancer: A combined exploratory analysis of three prospectively randomized phase III multicenter trials. Du Bois A, et al. J Clin Oncol 2010;28:1733-1739.". Ob/Gyn Clinical Alert 27(1):6-7, 5/2010.
42. Coleman RL. Laparoscopy vs Laparotomy for Endometrial Cancer Staging: The Lap2 Report. Commentary on, "Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study Lap2. Walker JL, et al. J Clin Oncol 2009;27:5331-5336.". Ob/Gyn Clinical Alert 26(12):95-96, 4/2010.
43. Coleman RL. Bethesda Guidelines for Lynch Syndrome Screening Appear to Improve the Amsterdam Criteria. Commentary on, "Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Walsh CS, et al. Gynecol Oncol 2009 Dec 22; Epub ahead of print.". Ob/Gyn Clinical Alert 26(11):85-86, 3/2010.
44. Coleman RL. The Next Iteration of the Radical Hysterectomy? Commentary on, "Resection of the embryologically defined uterovaginal (Mullerian) compartment and pelvic control in patients with cervical cancer: A prospective analysis. Hockel M, et al. Lancet Oncol 2009;10:683-692.". Ob/Gyn Clinical Alert 26(10):76-77, 2/2010.
45. Coleman, RL. Anti-angiogenesis Targeting Agents in Recurrent Ovarian Cancer: Now There Are Two? Commentary on, "Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Matulonis U, et al. J Clin Oncol 2009;27:5601-5606.". Ob/Gyn Clinical Alert 26(9):71-72, 1/2010.
46. Coleman RL. Special Feature: Moving the Bar in Primary Advanced Ovarian Cancer Therapy. Ob/Gyn Clinical Alert 26(8):62-64, 12/2009.
47. Coleman RL. Fertility-sparing Options for Ovarian Cancer Patients. Commentary on, "Fertility preservation in young women with epithelial ovarian cancer. Wright JD, et al., Cancer 2009 Aug 10; Epub ahead of print; doi: 10.1002/cncr.24461". Ob/Gyn Clinical Alert 26(6):43-44, 10/2009.
48. Coleman RL. Hormone Therapy and Ovarian Cancer: Another Affirmation. Commentary on, "Hormone therapy and ovarian cancer. Morch LS, et al. JAMA 2009;302:298-305". Ob/Gyn Clinical Alert 26(6):44-45, 10/2009.
49. Herzog TJ, Coleman RL. CA-125: What Does This Test Mean to You? Coping with Cancer 23(5):41, 9/2009.
50. Coleman RL. Incorporating Robotics in Gynecologic Oncology Training Programs. Commentary on, "Robotic Surgery in gynecologic oncology: Impact of fellowship training. Hoekstra AV, et al. Gynecol Oncol 2009;114:68-172.". Ob/Gyn Clinical Alert 26(5):38-39, 9/2009.
51. Coleman RL. Emergence of True "Individualized" Therapy: The PARP Inhibitors. Commentary on, "Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. Fong PC, et al. N Engl J Med 2009 June 24; Epub ahead of print.". Ob/Gyn Clinical Alert 26(4):30-31, 8/2009.
52. Coleman RL. Screening for Ovarian Cancer: One "Scissor Step" Made. Commentary on, "Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Menon U, et al. Lancet Oncol 2009;10:327-340.". Ob/Gyn Clinical Alert 26(3):22-23, 7/2009.
53. Coleman RL. Special Feature: Swing and Miss?!? Efforts in Front-line Ovarian Cancer Chemotherapy Development. Ob/Gyn Clinical Alert 26(2):14-16, 6/2009.
54. Coleman RL. PLCO: Where Are We Now? Commentary on, "Results from four rounds of ovarian cancer screening in a randomized trial. Partridge E, et al. Obstet Gynecol. 2009:112:775-782.". Ob/Gyn Clinical Alert 26(1):6-7, 5/2009.
55. Coleman RL. Commentary on, "Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Kitchner H, et al. Lancet 2009;373:125-136.". Ob/Gyn Clinical Alert 25(12):92-93, 4/2009.
56. Coleman RL. Special Feature: On the Origin of Ovarian Cancer . . Is it the Ovary? Ob/Gyn Clinical Alert 25(11):86-88, 3/2009.
57. Coleman RL. Commentary on, "'BRCAness' syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Tan DS, et al. J Clin Oncol 2008 Oct 27; Epub ahead of print. Ob/Gyn Clinical Alert 25(9):65-66, 1/2009.
58. Coleman RL. Special Feature: Maintenance Therapy for Ovarian Cancer: Are We There Yet? Ob/Gyn Clinical Alert 25(7):52-55, 11/2008.
59. Coleman RL. Commentary on, "Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Bansal N, et al. Obstet Gynecol 2008;112:64-70". Ob/Gyn Clinical Alert 25(6):45-46, 10/2008.
60. Coleman RL. Commentary on, "Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Mariani a, et al, Gynecol Oncol. 2008; 109:11-18". Ob/Gyn Clinical Alert 25(5):34-35, 9/2008.
61. Coleman RL, Levine DA. 44th Annual Meeting of the American Society of Clinical Oncology. Gynecol Oncol 110(2):123-4, 8/2008. PMID: 18649408.
62. Coleman RL. Commentary on, "Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Hensley M, et al. Gynecol Oncol. 2008;109:329-334.". Ob/Gyn Clinical Alert 25(4):27-28, 8/2008.
63. Coleman RL. Commentary on, "Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod. Van Seters M, et al. N Engl J Med. 2008;358:1465-1473.". Ob/Gyn Clinical Alert 25(3):20-21, 7/2008.
64. Coleman RL. Special Feature: Highlights from SGO 2008: Ovarian Cancer. Ob/Gyn Clinical Alert 25(3):21-24, 7/2008.
65. Coleman RL. Commentary on, "Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Thomas G, et al. Gynecol Oncol. 2008;108:317-325.". Ob/Gyn Clinical Alert 25(1):3-4, 5/2008.
66. Coleman RL. Commentary on, "Prentice RL, et al. J Natl Cancer Inst. 2007;99:1534-1543.". Ob/Gyn Clinical Alert 25(1):5-6, 5/2008.
67. Coleman RL. Commentary on, "Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Ferrandina G, et al. J Clin Oncol. 2008;26:890-896.". Ob/Gyn Clinical Alert 24(12):89-90, 4/2008.
68. Coleman RL. Commentary on, "Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. Van der Zee A, et al. J Clin Oncol. 2008;26:884-889.". Ob/Gyn Clinical Alert 24(12):92-93, 4/2008.
69. Coleman RL. Commentary on: "Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Yazbek J, et al. Lancet Oncol. 2008;9:124-131". Ob/Gyn Clinical Alert 24(11):83-84, 3/2008.
70. Coleman RL. Commentary on: "Therapeutic Vaccination for Dysplasia: Early Efficacy. Einstein MH, et al. Gynecol Oncol. 2007;106:453-460.". Ob/Gyn Clinical Alert 24(11):84-85, 3/2008.
71. Coleman RL. Commentary on: "Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. Lancaster JM, et al. Gynecol Oncol. 2007;107:159-162". Ob/Gyn Clinical Alert 24(8):62-63, 12/2007.
72. Coleman RL. Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep 9(6):469-71, 11/2007. PMID: 17991354.
73. Coleman RL. Commentary on, "Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Frumovitz M, et al. Obstet Gynecol. 2007;100:96-102". Ob/Gyn Clinical Alert 24(6):45-46, 10/2007.
74. Coleman RL. Commentary on, "Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. Callahan MJ, et al. J Clin Oncol 2007;25:3985-3990". Ob/Gyn Clinical Alert 24(6):44-45, 10/2007.
75. Coleman RL. Special Feature: Is there Value in CA125 Distinguishing Benign from Malignant Ovarian Tumors? Ob/Gyn Clinical Alert 24(6):46-47, 10/2007.
76. Coleman, RL. Commentary on, "Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Mutch DC, et al. J Clin Oncol.2007;25:2811-2828.". Ob/Gyn Clinical Alert 24(5):33-40, 9/2007.
77. Coleman Rl. Commentary on, "Reproductive and Sexual Function in Long-term Ovarian Cancer Survivors after Platinum-based Chemotherapy. Gershenson DM, et al. J Clin Oncol. 2007;19:2792-2797.". Ob/Gyn Clinical Alert 24(4):27-28, 8/2007.
78. Coleman RL. Commentary on, "Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. Garland S, on Behalf of the FUTURE I investigators. New Engl J Med. 2007;356:1928-1943.". Ob/Gyn Clinical Alert 24(3):21-22, 7/2007.
79. Coleman RL. Commentary on, "Coffee consumption and the risk of endometrial cancer: Evidence from a case-control study of female hormone-related cancers in Japan. Cancer Sci. 2007;98:411-415.". Ob/Gyn Clinical Alert 24(2):9-10, 6/2007.
80. Coleman RL. Special Feature: Highlights from the 38th Annual Meeting of The Society of Gynecologic Oncologists. Ob/Gyn Clinical Alert 24(2):12-16, 6/2007.
81. Coleman RL. Commentary on, "Prevalence of HPV infection among females in the United States. Dunne ER, et al. JAMA 2007;297:813-819.". Ob/Gyn Clinical Alert 24(1):5-6, 5/2007.
82. Coleman RL. Commentary on, "A prospective blinded evaluation of frozen section for the surgical management of endometrial cancer. Case AS, et al. Obstet Gynecol 2006;108:1375-1379.". Ob/Gyn Clinical Alert 23(11):83-84, 3/2007.
83. Coleman RL. 7th annual International Conference on Ovarian Cancer. Expert Rev Anticancer Ther 7(2):119-21, 2/2007. PMID: 17288523.
84. Coleman RL. Commentary on, "Reproductive risk factors for ovarian cancer in carriers of BRCA1 of BRCA2 mutations: a case-control study. McLaughlin JR, et al. Lancet Oncol 2007;8:26-34.". Ob/Gyn Clinical Alert 23(10):77-78, 2/2007.
85. Coleman RL. Commentary on, "What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Chi DS, et al. Gynecol Oncol 2006;103:559-564.". Ob/Gyn Clinical Alert 23(9):67-68, 1/2007.
86. Coleman RL. Commentary on, "Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Chan JK, et al. Cancer 2006;107:1823-1830.". Ob/Gyn Clinical Alert 22/8:60-61, 12/2006.
87. Coleman RL. Special Feature: Expanding the Treatment Options for Recurrent Ovarian Cancer Patients. Ob/Gyn Clinical Alert 22/7:53-56, 11/2006.
88. Coleman RL. Commentary on, "Gestational trophoblastic diseases::4.Presentation with persistent low positive human chorionic gonadotropin test results. Cole LA, et al. Gynecol Oncol. 2006;102:165-172". Ob/Gyn Clinical Alert 22/6:46-47, 10/2006.
89. Coleman RL. Commentary on, "Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or RCA2 Mutation. Finch A, et al. JAMA. 2006;296:185-192". Ob/Gyn Clinical Alert 22/6:42-43, 10/2006.
90. Coleman RL. Commentary on, "Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Thaker PH, et al. Nat Med. 2006;12:939-944". Ob/Gyn Clinical Alert 22/5:35-36, 9/2006.
91. Coleman RL. Commentary on, "Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Wright JD, et al. Cancer 2006;107:83-89.". Ob/Gyn Clinical Alert 22/4:28-29, 8/2006.
92. Coleman RL. Commentary on, "Adiponectin, insulin resistance and endometrial cancer. Soliman PT, et al. Cancer 2006;106:2376-2381.". Ob/Gyn Clinical Alert 22/3:20-21, 6/2006.
93. Coleman RL. Special Feature: Angiogenesis and the Strategic Target for Ovarian Cancer Therapy. Ob/Gyn Clinical Alert 23/2:14-15, 6/2006.
94. Coleman RL. Commentary on, "Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. Markman M, et al. J Clin Oncol 2006;24:1454-1458.". Ob/Gyn Clinical Alert 23/1:7, 5/2006.
95. Coleman RL. Commentary on, "Pulmonary embolism after major abdominal surgery in gynecologic oncology. Martino M, et al. Obstet Gynecol 2006;107:666-671.". Ob/Gyn Clinical Alert 23/1:3-4, 5/2006.
96. Coleman RL. Commentary on, "Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Randall M, et al. J Clin Oncol 2006:24:36-44.". Ob/Gyn Clinical Alert 22/11:83-84, 3/2006.
97. Coleman RL. Commentary on, "Diagnostic open laparoscopy in the management of advanced ovarian cancer. Angioli R, et al. Gynecol Oncol 2006;100:455-461.". Ob/Gyn Clinical Alert 22:89-91, 2006.
98. Coleman RL. Commentary on, "Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. Crawford SC, et al. J Clin Oncol 2005;23:8802-8811.". Ob/Gyn Clinical Alert 22:65-67, 2006.
99. Coleman RL. Commentary on, "Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Armstrong DK, et al. N Engl J Med 2006;354:34-43.". Ob/Gyn Clinical Alert 22:77-78, 2006.
100. Coleman RL. Commentary on, "Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominis myocutaneous flap reconstructive surgery. Awtrey CS, et al. Gynecol Oncol 2005;99:720-725.". Ob/Gyn Clinical Alert 22:69-70, 2006.
101. Coleman RL. Commentary on, "Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. Schmeler KM, et al. N Engl J Med 2006;354:261-269.". Ob/Gyn Clinical Alert 22:86-87, 2006.
102. Coleman RL. Commentary on, "Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. Barakat RR, et al. J Clin Oncol 2006;24:587-592.". Ob/Gyn Clinical Alert 22:92-93, 2006.
103. Coleman RL. Commentary on, "Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. Menon U, et al. J Clin Oncol 2005;23:7919-7926.". Ob/Gyn Clinical Alert 22/8:59-60, 12/2005.
104. Coleman RL. Commentary on, "Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005;15:593-600.". Ob/Gyn Clinical Alert 22/7:53-54, 11/2005.
105. Coleman RL. Commentary on, "Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. Ell K, et al. J Clin Oncol. 2005;23:3052-3060.". Ob/Gyn Clinical Alert 22/6:41-42, 10/2005.
106. Coleman RL. Commentary on, "Fertility-sparing surgery for ovarian low malignant potential tumors. Rao GG, et al. Gynecol Oncol. 2005;98:263-266.". Ob/Gyn Clinical Alert 22/5:34-35, 9/2005.
107. Coleman RL. Commentary on, "Proteomic profiling in ovarian cancer: is it plausible? Baggerly KA, et al. J Natl Cancer Inst. 2005;97:307-309.". Ob/Gyn Clinical Alert 22/2:11-12, 6/2005.
108. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother 6(7):1269-75, 6/2005. PMID: 15957979.
109. Coleman RL. Special Feature: Systematic lymphadenectomy in ovarian cancer surgery: now we know! Ob/Gyn Clinical Alert 22/2:14-15, 6/2005.
110. Coleman RL. Commentary on, "High tech prognostication for ovarian cancer patients. Hartmann LC, et al. Clin Cancer Res 2005;11(6):2149-2155.". Ob/Gyn Clinical Alert 22/1:3-4, 5/2005.
111. Coleman RL. Commentary on, "Does it matter how ovaries removed prophylactically are processed pathologically? Powell B, et al. J Clin Oncol. 2005;23:127-132.". Ob/Gyn Clinical Alert 21/12:91-92, 4/2005.
112. Coleman RL. Commentary on, "Immunotherapy for consolidation treatment of ovarian cancer--Is this the one? Berek JS, et al. J Clin Oncol. 2004;22:3507-3516.". Ob/Gyn Clinical Alert 21/10:75-77, 2/2005.
113. Coleman RL. Commentary on, "Randomized Phase III Trial of Cisplatin with or without Topotecan in Carcinoma of the Uterine Cervix. Long HJ, et al. J Clin Oncol. 2005;Jun 6; [Epub ahead of print].". Ob/Gyn Clinical Alert 22/408:26-28, 2005.
114. Coleman RL. Commentary on, "Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Berek JS, Taylor PT, Gordon A, et al. J Clin Oncol 2004;22:3507-3516.". Curr Oncol Rep 7:417-418, 2005.
115. Coleman RL. Commentary on, "Secondary surgical cytoreduction for advanced ovarian carcinoma. Rose PG, et al. N Engl J Med. 2004;351(24):2489-2497.". Ob/Gyn Clinical Alert 21:82-83, 2005.
116. Coleman RL. Commentary on, "Surgical staging for patients presenting with grade 1 endometrial carcinoma. Ben-Shachar I, et al. Obstet Gynecol. 2005;105:487-493.". Ob/Gyn Clinical Alert 22:19-20, 2005.
117. Coleman RL. Commentary on, "Update in the medical management of ovarian cancer. Markman M. Oncol Special Ed 2005,8:125-8.". Oncol Special Ed 8:126, 2005.
118. Coleman RL. Commentary on, "Validating intraoperative pathology: frozen section. Geomini P, et al. Gynecol Oncol. 2005;96:1-9.". Ob/Gyn Clinical Alert 21:94-95, 2005.
119. Coleman RL. Commentary on, "Validation of referral guidelines for women with pelvic masses. Im SS, et al. Obstet Gynecol. 2005;105:35-41.". Ob/Gyn Clinical Alert 21:85-86, 2005.
120. Coleman RL. Commentary. To RECIST or not to RECIST: What is the question? . Am J Oncol Rev 4:245-7, 2005.
121. Coleman RL. Special Feature: Ovarian Cancer: Can One Be Too Old for Cancer Care? Ob/Gyn Clinical Alert 22:54-56, 2005.
122. Coleman RL. Commentary on, "BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Lavie O, et al. Gynecol Oncol 2004;92:521-524.". Ob/Gyn Clinical Alert 20:92-93, 2004.
123. Coleman RL. Commentary on, "Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white and black women in the United States. Wang S, et al. Cancer 2004;100:1035-1044.". Ob/Gyn Clinical Alert 20:91-92, 2004.
124. Coleman RL. Commentary on, "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women. Harper D, et al. Lancet 2004;364:1757-1765.". Ob/Gyn Clinical Alert 21:68-70, 2004.
125. Coleman RL. Commentary on, "Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Goff BA, et al. JAMA 2004;291:2705-2712).". Ob/Gyn Clinical Alert 21:33-34, 2004.
126. Coleman RL. Commentary on, "Myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? Lindauer J, et al. Gynecol Oncol 2003;91(3):547-551.". Ob/Gyn Clinical Alert 20:82-83, 2004.
127. Coleman RL. Commentary on, "Ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Donato ML, et al. Bone Marrow Transplant 2004 May 3 (E-pub ahead of print).". Ob/Gyn Clinical Alert 21:19-20, 2004.
128. Coleman RL. Commentary on, "Prediction of optimal vs suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Berchuck A, et al. Am J Obstet Gynecol 2004;190(4):910-925.". Ob/Gyn Clinical Alert 21:28-29, 2004.
129. Coleman RL. Commentary on, "Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Fauvet R, et al. Cancer 2004;100:1145-1151.". Ob/Gyn Clinical Alert 21:4-5, 2004.
130. Coleman RL. Commentary on, "Surgical staging of ovarian low malignant potential tumors. Rao GG, et al. Obstet Gynecol 2004;104:261-266.". Ob/Gyn Clinical Alert 21:47-48, 2004.
131. Coleman RL. Commentary on, "Timing isn't everything, right? McMeekin DS, et al. Gynecol Oncol 2004;95(1):157-164.". Ob/Gyn Clinical Alert 21:61-62, 2004.
132. Coleman RL. Commentary on, "Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Huh WK, et al. Gynecol Oncol 2003;91:470-5.". Ob/Gyn Clinical Alert 20:73-75, 2004.
133. Coleman RL. Commentary on, "Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Huh WK, et al. Gynecol Oncol 2003;91:470-5.". Women's Oncol Rev 4:41-42, 2004.
134. Coleman RL. Commentary on, "YKL-40 and ovarian cancer. Dupont J, et al. J Clin Oncol 2004;22:3330-3339.". Ob/Gyn Clinical Alert 21:44-45, 2004.
135. Coleman RL. Special Feature: Adjuvant radiation determined for intermediate risk endometrial cancer! Or has it? . Ob/Gyn Clinical Alert 21(2):13-15, 2004.
136. Coleman RL. Special Feature: Chemotherapy sensitivity/resistance assays is gynecologic cancer: are we there yet? Ob/Gyn Clinical Alert 21(7):53-56, 2004.
137. Coleman RL. Advances in ovarian cancer, relapsed ovarian cancer: Challenges and management strategics. Physician's Education Resource 2:1, 11/2003.
138. Coleman RL. Commentary on, "A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Rose PG, et al. Gynecol Oncol 2003;88:130-5.". Women's Oncol Rev 3:69-70, 2003.
139. Drake R Coleman RL. Commentary on, "Anorectal dysfunction after surgical treatment for cervical cancer. Sood AK, et al. J Am Coll Surg 2002;195:513-19.". Women's Oncol Rev 3:53-4, 2003.
140. Rao G Coleman RL. Commentary on, "Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Markman M, et al. J Clin Oncol 2003;21:2460-5.". Women's Oncol Rev 3:217-218, 2003.
141. Fujiwara K Coleman RL. Commentary on, "Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Chan YM, et al. Gynecol Oncol 2003;88:9-16.". Women's Oncol Rev 3:65-6, 2003.
142. Coleman RL. Commentary on, "Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. Hoskins PJ, et al. J Clin Oncol 2003;21:3495-501.". Women's Oncol Rev 3:291-92, 2003.
143. Drake R Coleman RL. Commentary on, "Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. Van Patten, et al., J Clin Oncol 2002;20:1449-55.". Women's Oncol Rev 2:307-8, 2002.
144. Coleman RL. Commentary on, "In vivo molecular chemotherapy and noninvasive imaging with an infectivity enhanced adenovirus. Hemminski, et al., J Natl Cancer Inst 2002;94:741-9.". Women's Oncol Rev 2:301-2, 2002.
145. Coleman RL. Commentary on, "Menopausal hormone replacement therapy and risk of ovarian cancer. Lacey, et al., JAMA 2002;288:344-41.". Women's Oncol Rev 2:303-4, 2002.
146. Wolf JK Coleman RL. Commentary on, "Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYZ-015(dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. Vasey, et al. J Clin Oncol 2002;20:1562-9.". Women's Oncol Rev 2:325-7, 2002.
147. Rao GG Coleman RL. Commentary on, "Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Rebbeck, et al., N Engl J Med 2002;346:1616-22.". Women's Oncol Rev 2:323-4, 2002.
148. Coleman RL. Commentary on, "Simultaneously detected endometrial and ovarian carcinomas - a prospective clinicopathologic study of 74 cases: a Gynecologic Oncology Group study. Zaino et al., Gynecol Oncol 2001;83:255-62.". Women's Oncol Rev 2:57-8, 2002.
149. Coleman RL Levenback C. Laparoscopic sentinel node procedure in patients with cervical cancer. Journal of Clinical Oncology 20(10):2603, 2002.
150. Wright JD, Powell MA, Coleman RL, Herzog TJ. Lower extremity lymphedema. Women's Oncol Rev 2:269-276, 2002.
151. Mirhashemi R, Lambrou N, Coleman RL. Vaginal reconstruction in gynecologic oncology. Women's Oncol Rev 2:13-18, 2002.
152. Coleman RL. Commentary on, "Combination Chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. Markman, Et al., J Clin Oncol 2001; 19:1901-5.". Women's Oncol Rev 1:159-60, 2001.
153. Coleman RL. Commentary on, "Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial, Solomon et al., J Natl Cancer Inst 2001:93:291-9.". Women's Oncol Rev 1:45-6, 2001.
154. Coleman RL. Commentary on, "Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Rodriguez, et al., JAMA 2001; 285:1460-5.". Women's Oncol Rev 1:163-5, 2001.
155. Coleman RL. Commentary on, "Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Van Trappen, et al., Lancet 2001;357:15-20.". Women's Oncol Rev 1:49-50, 2001.
156. Coleman RL. Commentary on, "Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Boruta, et al., Gynecol Oncol 2001;81:82-7.". Women's Oncol Rev 1:155-6, 2001.
157. Lea J Coleman RL. Commentary on, "Use of GnRH analogs for function protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Pereyra-Pacheco, et al., Gynecol Oncol 2001;82:312-6.". Women's Oncol Rev 1:371-2, 2001.
158. Coleman RL. Extraperitoneal approaches to lymphadenectomy. (Gershenson D, ed) . Operative Techniques in Gynecologic Surgery 1:31-5, 2001.
159. Coleman RL. Lymphatic mapping in cervix cancer. (Levenback C, guest ed) . Operative Techniques in Gynecologic Surgery 6(1):33-37, 2001.
160. Jones DB, Simmang CL, Coleman RL. The emerging role of laparoscopy in bowel surgery. Operative Techniques in Gynecologic Surgery 6(2):105-12, 2001.
161. Coleman RL. Vulvar lymphatic mapping: current perspectives. Women's Oncol Rev 1:17-22, 2001.
162. Coleman RL. Bowel complications of gynecologic surgery. Clinical Consultations in Obstet Gynecol 8(2):91-99, 1996.
163. Coleman RL. Carcinoma of the uterine cervix: Chemoradiotherapy. Clinical Consultations in Obstet Gynecol 7(2):141-146, 1995.
164. Coleman RL. Cervical carcinoma - an overview. J Natl Can Registr Assoc 20:10, 1994.
165. Coleman RL. Cervical carcinoma: Causes and prevention. American Council on Science and Medicine 12:7-9, 1992.

Editorials

1. Coleman RL. Lymphatic mapping for vulvar cancer: ready for "prime-time?". Curr Oncol Rep 10(6):493-6, 11/2008. PMID: 18928663.
2. Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do we have one? Cancer 113(4):665-7, 8/2008. PMID: 18623195.
3. Coleman RL. Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified? Curr Oncol Rep 8:439-440, 11/2006. PMID: 17091543.
4. Coleman RL. Primary vaginal melanoma: a rare and problematic clinical entity. Ann Surg Oncol 11:4-6, 2004. PMID: 14699024.
5. Coleman RL. Women's oncology in the twenty-first century. Women's Oncol Rev 1:1, 2003.
6. Coleman RL. Vulvar lymphatic mapping: coming of age? 9:823-5, 11/2002. PMID: 12417500.
Other Articles
1. GCF Telephone Education Workshop on Clinical Trials for Recurrent Ovarian Cancer Phase III and IV. 7/2005.

Abstracts

1. Coleman RL, Moon J, Sood AK, Delmore JE, Bonebrake AJ, Anderson GL, Alberts DS, Markman M. Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904. 2011 ASCO Annual Meeting, Chicago, IL (#5015), 2012.
2. B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. 2011 ASCO Annual Meeting, Chicago, IL (#5012), 2011.
3. R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. 2011 ASCO Annual Meeting, Chicago, IL (#5017), 2011.
4. R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. 2011 ASCO Annual Meeting, Chicago, IL (#5045), 2011.
5. L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galbincea, T. A. Johnston, M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman, D. M. Gershenson, T. W. Burke, J. Wolf, K. H. Lu. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. 2011 ASCO Annual Meeting, Chicago, IL (#5016), 2011.
6. Coleman RL, Brady B, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nab-paclitaxel (Abraxane) in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A gynecologic oncology group (GOG) study. 2010 ASCO Annual Meeting, Chicago, IL (#5010), 6/2010.
7. Moroney J, Helgason T, Hong D, Coleman R, Moulder S, Bodurka D, Kurzrock R. A Phase I trial of liposomal doxorubicin, bevacizumab and temsirolimus in patients with advanced malignancy: An interim reporting of outcomes in 59 patients with gynecologic cancer. SGO 41st Annual Meeting on Women's Cancer (#30), 3/2010.
8. Carroll A, Armaiz Pena G, Coleman R, Kim S, Lopez-Berestein G, Mangala S, Nick A, Sood A, Spannuth W, Stone R. Breaking scaffolds: Targeting paxillin in ovarian cancer. SGO 41st Annual Meeting on Women's Cancer (#280), 3/2010.
9. Brown J, Sood A, Ramirez P, Ramondetta L, Coleman R, Levenback C, Jung M, Wolf J. Combination gemcitabine and cisplatin are highly active in endometrial carcinoma: Results of a prospective phase II trial. SGO 41st Annual Meeting on Women's Cancer (#49), 3/2010.
10. Lin Y, Stone R, Merritt W, Kamat A, Nick A, Spannuth W, Carroll A, Langley R, Coleman R, Sood A. Dual metronomic chemotherapy results in potent antiangiogenic effects in ovarian carcinoma. SGO 41st Annual Meeting on Women's Cancer (#395), 3/2010.
11. Landen C Jr, Goodman B, Han H, Nick A, Stone R, Jennings N, Alvarez R, Coleman R, Lopez-Berestein G, Sood A. Dual threat: Targeting the notch ligand Jagged1 in both tumor and stroma in ovarian cancer. SGO 41st Annual Meeting on Women's Cancer (#270), 3/2010.
12. Stone R, Lee J, Nam E, Nick A, Shahzad M, Mao S, Gooya J, Jackson D, Coleman R, Sood A. Improving delivery of cytotoxic payload to uterine cancer. SGO 41st Annual Meeting on Women's Cancer (#418), 3/2010.
13. Milam M, Tao X, Harrell R, Bassett R, dos Reis R, Coleman R, Ramirez P. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. SGO 41st Annual Meeting on Women's Cancer (#300), 3/2010.
14. Nick A, Stone R, Spannuth W, Landen C Jr, Carroll A, Han H, Deavers M, Lopez-Berestein G, Coleman R, Sood A. p130Cas and tumor angiogenesis: Moving beyond bevacizumab. SGO 41st Annual Meeting on Women's Cancer (#414), 3/2010.
15. Slomovitz B, Schmeler K, Miller D, Lu K, Ramirez P, Caputo T, Coleman R, Burke T, Gershenson D, Wolf J. Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. SGO 41st Annual Meeting on Women's Cancer (#13), 3/2010.
16. Sood A, Bornmann W, Coleman R, Fernandez A, Hennessy B, Lin Y, Lopez-Berestein G, Nick A, Stone R, Vivas-Mejia P. Re-engineering imatinib to make it safer and more effective. SGO 41st Annual Meeting on Women's Cancer (#281), 3/2010.
17. Spannuth W, Kumar S, Masood R, Nick A, Lin Y, Merritt W, Coleman R, Tice D, Gill P, Sood A. Therapeutic targeting of EphB4 with a novel monoclonal antibody. SGO 41st Annual Meeting on Women's Cancer (#352), 3/2010.
18. S. Uppal, M. Frumovitz, R. dos Reis, A.M. Nick, R.L. Coleman, P.T. Soliman, K.M. Schmeler, P.T. Ramirez. Association of Body Mass Index and Time under Anesthesia with Laparoscopic Surgical Complications. 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL (#298), 2010.
19. M.J. Worley, C. Anwandter, C.C. Sun, R. Dos Reis, A.M. Nick, M. Frumovitz, R.L. Coleman, P.T. Soliman, K.M. Schmeler, P.T. Ramirez. Impact of Surgeon Volume on Patient Outcome in Gynecologic Laparoscopy. 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL (#184), 2010.
20. B. Zand, E.D. Euscher, P.T. Soliman, K.M. Schmeler, R.L. Coleman, A. Jhingran, M. Frumovitz, L.M. Ramondetta, P.T. Ramirez. Rate of Para-Aortic Lymph Node Micrometastasis in Patients with Locally Advanced Cervical Cancer. 39th Global Congress of Minimally Invasive Gynecology Annual Meeting of the AAGL (#12), 2010.
21. Levenback C, Tian C, Coleman RL, Gold M, Fowler J, Judson P. Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study. 16th International Meeting of the European Society for Gynaecological Oncology (ESGO 16), Belgrade, Serbia (#A-171-0003-01429), 10/2009.
22. Moroney JW, Coleman RL, Hong DS, Wheler JJ, Ng C, Bodurka DC, Falchook A, Naing A, Helgason T, Kuzrock R. A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. 2009 ASCO Annual Meeting, Orlando, FL (#e13508), 2009.
23. Tao S, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Gershenson DM, Brown J. Antiangiogenic therapy for granulosa cell tumors of the ovary. 2009 ASCO Annual Meeting, Orlando, FL (#5574), 2009.
24. Stone RL, Nick AM, Spannuth WA, Bonome T, Lutgendorf S, DeGeest K, Merritt W, Lin YG, Gershenson DM, Coleman RL, Birrer MJ, Sood AK. Focal adhesion kinase is a new focus for antiangiogenesis therapy in ovarian cancer. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#55), 2009.
25. Sood AK, Mangala LS, Han H, Lu C, Ali-Fehmi R, Stone R, Munkarah A, Spannuth W, Nick AM, Lee J, Shahzad M, Guven E, Coleman RL, Denkbas E, Birrer MJ, Lopez-Berestein G. In vivo angiogenic gene silencing using chitosan nanoparticles in ovarian carcinoma. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#268), 2009.
26. Merritt W, Hwant J, Lin YG, Spannuth WA, Nick AM, Landen CN, Kamat AA, Coffman K, Bruckheimer E, Gershenson DM, Coleman RL, Sood AK. Inhibition of EphA2 activity demonstrates significant antiangiogenic and antitumor effects in endometrial carcinoma. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#154), 2009.
27. Landen CN, Goodman BW, Nick AM, Armaiz-Pena GN, Danes CG, Stone RL, Shahzad MM, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Sood AK. Markers for discovering stemness in ovarian cancer. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#277), 2009.
28. Soliman PT, Celestino J, Finklelstein S, Broaddus R, Westin S, Schmeler KM, Lu KH, Coleman RL. Molecular profiling in the diagnosis of synchronous primary cancers of the endometrium and ovary. 2009 ASCO Annual Meeting, Orlando, FL (#e16500), 2009.
29. Coleman RL, Kamat A, Iyer R, Kundra V, Garcia M, Jaffe RB, Sood AK. Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. 2009 ASCO Annual Meeting, Orlando, FL (#5549), 2009.
30. Farley JH, Sill M, Walker JL, Schilder RJ, Thigpen JT, Coleman RL, Miller BE. Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group. 2009 ASCO Annual Meeting, Orlando, FL (#5521), 2009.
31. Lin YG, Merritt WM, Spannuth WA, Nick AM, Stone RL, Tsinberg P, Coleman RL, Birrer MJ, Bischoff F, Sood AK. Rare circulating tumor cells can be reliably and efficiently detected using a novel microfluidics and micro-electromechanical systems (MEMS)-based rare cell recovery platform: Preclinical and clinical data. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#230), 2009.
32. Levenback CF, Tian C, Coleman RL, Gold MA, Fowler JM, Judson PL. Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study. 2009 ASCO Annual Meeting, Orlando, FL (#5505), 2009.
33. Spannuth WA, Lin YG, Merritt WM, Nick AM, Stone RL, Mangala SL, Armaiz-Pena GN, Landen CN, Grasso L, Coleman RL, Sood AK. Therapeutic efficacy of folate receptor α blockade with MORAb-003 in ovarian cancer. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#315), 2009.
34. Nick AM, Spannuth WA, Landen CN, Kamat AA, Han L, Lin YG, Merritt WM, Stone RL, Jennings NB, Kim S, Mangala LS, Deavers M, Lopez-Berestein G, Coleman RL, Sood AK. Therapeutic gene silencing in ovarian carcinoma: Making the case for p130cas. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#239), 2009.
35. Nick AM, Mangala LS, Zuzel V, Schmandt RE, Halder JB, Armaiz-Pena GN, Spannuth WA, Lin YG, Kim SW, Shahzad M, Lee J, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B: Novel mechanisms and reversing cisplatin resistance in ovarian carcinoma. SGO 40th Annual Meeting on Women's Cancer, San Antonio, TX (#240), 2009.
36. Herzog TJ, Fader AN, Fensterer JE, Gallion HH, Krivak TC, Coleman RL. A chemoresponse assay and survival in primary ovarian cancer. 44th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#08-AB-35083-ASCOAM), 5/2008.
37. Bast RC, Iyer R, Hu W, Kavanagh J, Coleman R, Levenback C, Sood A, Wolf J, Gershenson D, Markman M, Fu S. A phase II study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. 44th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#08-AB-35203-ASCOAM), 5/2008.
38. Slomovitz BM, Lu KH, Johnston T, Munsell M, Ramondetta LM, Broaddus RR, Coleman RL, Walker C, Gershenson DM, Burke TW, Wolf J. A phase II study of oral mammalian target of rapamycin (MTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). 44th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#08-AB-34086-ASCOAM), 5/2008.
39. Lin Y, Hwang JY, Mangala L, Fok J, Merritt W, Spannuth W, Nick A, Vivas-Mejia P, Deavers M, Coleman R, Lopez-Berestein G, Mehta K, Sood A. Biological and therapeutic implications of tissue transglutaminase (TG2) silencing in advanced ovarian carcinoma. 99th AACR Annual Meeting, San Diego, CA (#1202), 2008.
40. Kim SW, Nick A, Mangala L, Spannuth W, Lee JW, Shahzad M, Vivas-Mejia P, Coleman R, Lopez-Berestein G, Sood A. Biological significance of paxillin in ovarian carcinoma. 99th AACR Annual Meeting, San Diego, CA (#305), 2008.
41. Merritt W, Lin Y, Han L, Kamat A, Spannuth W, Schmandt R, Pennacchio L, Cheng JF, Zeidan A, Wang H, Gray J, Mok S, Birrer M, Lopez-Berestein G, Coleman R, Bar-Eli M, Sood A. Decreased expression of RNA interference machinery, Dicer and Drosha, may impact the efficacy of RNAi-targeted therapies in ovarian cancer. 99th AACR Annual Meeting, San Diego, CA (#1568), 2008.
42. Lin Y, Merritt W, Spannuth W, Nick A, Birrer M, Tsinberg P, Coleman R, Bischoff F, Sood A. Efficient recovery of circulating tumor cells (CTC) using a novel micro-electro-mechanical systems (MEMS)-based platform. 99th AACR Annual Meeting, San Diego, CA (#LB-298), 2008.
43. Armstrong DK, Bicher A, Coleman RL, Gibbon DG, Glenn D, Old L, Senzer NN, Schneeweiss A, Verheijen RH, White AJ, Weil S. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. 44th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#5500), 2008.
44. Kamat AA, Merritt WM, Lin YG, Coffey D, Nugent E, Han LY, Spannuth W, Nick A, Landen CN, Broaddus R, Gershenson DM, Coleman RL, Sood AK. Impact of EphA2 overexpression on clinical outcome in uterine cancer: Molecular explanations. SGO 39th Annual Meeting on Women's Cancer, Tampa, FL (#10), 2008.
45. Kamat A, Merritt W, Lin Y, Coffey D, Nugent E, Han L, Landen C, Broaddus R, Coleman R, Gershenson D, Sood A. Molecular basis for the impact of EphA2 overexpression on clinical outcome in uterine cancer. 99th AACR Annual Meeting, 2008; San Diego, CA (#5562), 2008.
46. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. SGO 39th Annual Meeting on Women's Cancer, Tampa, FL (#7), 2008.
47. Coleman, R. Sentinel Node (SN) Biopsy in Patients with Vulvar Cancer, The Gynecologic Oncology Group (GOG) Experience. IGCS 12th Biennial Meeting, Bangkok, Thailand (#2008-1124), 2008.
48. Spannuth W, Nick A, Jennings N, Lin Y, Merritt W, Thaker P, Kamat A, Han L, Tonra J, Ellis L, Coleman R, Sood A. The clinical and functional relevance of VEGFR on ovarian cancer cells. 99th AACR Annual Meeting, San Diego, CA (#3430), 2008.
49. Landen CN, Coleman R, Milam MR, Johnston T, Iyer R, Gershenson DM, Ramirez P. A phase I trial of the proteosome inhibitor PS-341 in combination with carboplatin in platinum and taxane resistant ovarian cancer patients. 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#5558), 2007.
50. Lu C, Bonome T, Li Y, Kamat A, Halder JB, Lin Y, Merritt W, Schmandt R, Coleman R, Gershenson D, Jaffe R, Birrer M, Sood A. Alterations in endothelial cell gene expression in human ovarian cancer. 98th AACR Annual Meeting, Los Angeles, CA (#3011), 2007.
51. Kavanagh JJ, Hu W, Fu S, Deavers M, Moore C, Coleman RL, Levenback CF, Shen D, Mueller P, Gershenson DM, Zheng H, Li YF. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#5582), 2007.
52. Sood AK, Lopez-Berestein G, Halder JB, Sanguino A, Kamat AA, Landen CN, Han LY, Lin YG, Merritt WM, Coleman RL. Characterization and safety of in vivo small interfering RNA delivery in neutral nanoparticles. SGO 38th Annual Meeting on Women's Cancer, San Diego, CA (#6), 2007.
53. Kamat AA, Sood AK, Merritt WM, Lin YG, Han LY, Broaddus R, Nugent E, Landen CN, Coleman RL, Gershenson DM. Clinical and biological significance of the vascular endothelial growth factor pathway in endometrial cancer. SGO 38th Annual Meeting on Women's Cancer, San Diego, CA (#71), 2007.
54. Merritt WM, Sood AK, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Coleman RL, Mok SC, Birrer M. Decreased expression of RNA interference machinery, Dicer and Drosha, is associated with poor outcome in patients with ovarian cancer. SGO 38th Annual Meeting on Women's Cancer, San Diego, CA (#5), 2007.
55. Schmeler KM, Sun CC, Bodurka Dc, Deavers MT, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary. 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#5571), 2007.
56. Phillips M, Armstrong D, Coleman R, Weil S, Arseneau J, Glenn D, Puls L, Senzer N, Torres J, White A. Novel phase II study design of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum-sensitive ovarian cancer in first relapse. 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#5583), 2007.
57. Lin Y, Merritt W, Fiterman D, Armaiz-Pena G, Spannuth W, Gershenson D, Coleman R, Sood A. Targeting aurora kinase inhibits tumorigenesis in ovarian cancer. 98th AACR Annual Meeting, Los Angeles, CA (#4357), 2007.
58. Halder J, Lin R, Merritt W, Kamat A, Han L, Kim TJ, Lu C, Coleman R, Sood A. Therapeutic efficacy of a novel FAK inhibitor TAE226 in ovarian carcinoma. 98th AACR Annual Meeting, Los Angeles, CA (#3751), 2007.
59. Spannuth W, Jennings N, Lin Y, Merritt W, Thaker P, Kamat A, Han L, Ellis L, Coleman R, Sood A. VEGFR2 promotes migration and invasion on ovarian cancer cells. 98th AACR Annual Meeting, Los Angeles, CA (#4403), 2007.
60. Naumann RW, Coleman RL. Changing patterns of care in the treatment of early-stage endometrial cancer. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA, 2006.
61. Lu C, Landen C, Kim TJ, Kamat A, Han L, Li Y, Jennings N, Halder JB, Coleman R, Jaffe R, Sood A. Dual targeting of endothelial cells and pericytes in antivascular therapy for human ovarian cancer. Proc Amer Assoc Cancer Res 47 (#1752), 2006.
62. Coleman RL, Herzog TJ, Barter JF, Gordon AN, Sun S, Rackoff W. Early increases in CA-125 after treatment with Doxil or topotecan are not always reflective of response in patients with recurrent ovarian cancer. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#70), 2006.
63. Smith J, Yu Jiang, Saucier J, Coleman R, Ramirez P. Evaluation of an aromatase inhibitor, letrozole, for the prevention of ovarian tumor growth in a human ovarian cancer xenograft model. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#320), 2006.
64. Halder JB, Landen C, Li Y, Jennings N, Kamat A, Han L, Lin Y, Merritt W, Schmandt R, Coleman R, Sood AK, Lutgendorf S. FAK silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#27), 2006.
65. Coleman RL, Ramirez PT, Slomovitz BM, Levenback C. Laparoscopic extraperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer: Histopathologic findings and correlation with PET-CT imaging studies. 42nd Annual Meeting American Society of Clinical Oncology (ASCO), Atlanta, GA (#5014), 2006.
66. Kamat A, Kim TJ, Landen C, Lu C, Han L, Lin Y, Thaker P, Merritt W, Coleman R, Gershenson D, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#25), 2006.
67. Slomovitz B, Lu K, Burke TW, Soliman PT, Schmeler K, Munsell M, Johnston T, Coleman R, Ramondetta L, Gershenson DM, Wolf J. mTOR is a rational target for the treatment of endometrial cancer: Preliminary results of a phase II study of RAD001 for patients with recurrent endometrial cancer. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#253), 2006.
68. Slomovitz BM, Coleman RL, Levenback C, Jung M, Gershenson DM, Wolf J. Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. 42nd Annual Meeting American Society of Clinical Oncology (ASCO), Atlanta, GA (#5090), 2006.
69. Milam MR, Ramirez P, Lu K, Bassett R, Coleman R, Slomovitz B, Sood AK. Supracervical hysterectomy does not impact clinical outcome in patients with epithelial ovarian cancer: A case-control analysis. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#362), 2006.
70. Thaker P, Lu Chunhua, Landen CN, Han L, Kamat AA, Coleman RL, Gershenson DM, Fidler IJ, Sood AK. Vascular remodeling with direct intraovarian injection of tumor cells. SGO 37th Annual Meeting on Women's Cancer, Palm Springs, CA (#391), 2006.
71. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Ramirez PT, Gershenson DM. A Phase II Study of Imatinib Mesylate in Patients with Recurrent Platinum-Resistant, Taxane-Resistant Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer. SGO 36th Annual Meeting on Women's Cancer, Miami, FL, 2005.
72. Slomovitz BM, Coleman RL, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM, Burke TW, Lu KH. Is there a survival difference between clear cell and serous carcinoma of the endometrium? : A stage and age-matched cohort study. 41st Annual Meeting American Society of Clinical Oncology (ASCO), Orlando, FL (#5081), 2005.
73. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Levenback C. Utility of Preoperative Lymphoscintigraphy in Patients Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy for Cervical Cancer. SGO 36th Annual Meeting on Women's Cancer, Miami, FL, 2005.
74. Frumovitz M, Coleman RL, Gayed I, Ramirez P, Wolf J, Levenback C. Utility of preoperative lymphoscintigraphy (LSG) in patients undergoing radical hysterectomy and pelvic lymphadenectomy for cervical cancer. 4th Biennial International Sentinel Node Congress, Los Angeles, CA, 12/2004.
75. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Fertility-sparing surgery for ovarian tumors of low malignant potential: a multicenter analysis. 50th Annual American College of Obstetricians and Gynecologists (ACOG) District VII Meeting, Washington, DC, 10/2004.
76. Alvarez RD, Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM. Weekly Topotecan as salvage therapy in relapsed ovarian cancer: a retrospective analysis. 10th Biennial International Gynaecologic Cancer Society Meeting (IGCS), Edinburgh, Scotland, 10/2004.
77. Coleman R, Herzog T, Hosford S, Sevin B-U, Wells A, Fiori L, Gallion H. An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer. 40th Annual Meeting American Society of Clinical Oncology (ASCO), New Orleans, LA (#5134), 6/2004.
78. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Muller CY, Miller DS, Schorge JO. Is Staging of Ovarian LMP Tumors Worth the Effort? A Multicenter Study of 229 Patients. SGO 35th Annual Meeting on Women's Cancer, San Diego, CA, 2004.
79. Rao G, Coleman RL, Rogers P, Nguyen P. Phase I Clinical Trial of Weekly Paclitaxel, Weekly Carboplatin and Concurrent Radiotherapy for Locally Advanced Cervical Cancer. SGO 35th Annual Meeting on Women's Cancer, San Diego, CA, 2004.
80. Rao GG, Coleman RL, Muller CY, Miller DS, Schorge JO. Ovarian tumors of low malignant potential: Is staging worth the effort?. 32nd Annual Meeting Western Association of Gynecologic Oncologists (WAGO), Steamboat Springs, CO, 6/2003.
81. Schorge JO, Lea JS, Rajanbabu R, Kurien A, Elias KJ, Coleman RL, Miller DS, Ashfaq R. P16 as a molecular biomarker of cervical adenocarcinoma. NEAGO, 6/2003.
82. Coleman R, Santoso JT, Lucci J, Schafer I. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. 39th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL, (#1892), 5/2003.
83. Coleman RL. Tumor board: Still worth it?. 39th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (#1981), 5/2003.
84. Corton MM, Wai CY, Vakill B, Boreham MK, Schaffer JI, Coleman RL. Comprehensive pelvic dissection course improves ob/gyn resident proficiency in surgical anatomy. CREOG & APGO Annual Meeting Anaheim, CA, 3/2003.
85. Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller, DS, Schorge JO. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. 34th Annual Meeting Society of Gynecologic Oncologists (SGO), New Orleans, LA (#12), 2/2003.
86. Lea JS, Kurien A, Coleman RL, Miller DS, Muller CY. Aberrant p16 Methylation Is a Target for Tobacco Associated DNA Damage in Squamous Cell Cervical Cancer. SGO 34th Annual Meeting on Women's Cancer (#35), 2003.
87. Lea, JS, Coleman RL, Garner EIO, Duska LR, Miller DS, Schorge JO. Predictors of Recurrent Low- and High-Risk Stage IB1 Cervical Adenocarcinoma: A Multicenter Study of 229 Patients. SGO 34th Annual Meeting on Women's Cancer (#146), 2003.
88. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor Board in Gynecologic Oncology. SGO 34th Annual Meeting on Women's Cancer (#113), 2003.
89. Rao GG, Rogers P, Coleman RL. Phase I study of weekly paclitaxel (P) and carboplatin (C) with concurrent radiotherapy as first line treatment in locally advanced cervical cancer. American Society of Clinical Oncology (ASCO), Orlando, FL, 5/2002.
90. Coleman RL. Effects of a laboratory-based skills curriculum on laparoscopic proficiency: A randomized trial. CREOG & APGO Annual Meeting, Dallas, TX, 3/2002.
91. Lin WM, Michalopulos EA, Coleman RL, Ashfaq R, Miller DS, Muller CY. P53 codon 72 polymorphism (ARG/ARG) and HPV 16 E6 variant (L83V) are more prevalent in hispanics with cervical dysplasia. Western Association of Gynecologic Oncologists (WAGO) 30th Annual Meeting, Sun Valley, Idaho, 6/2001.
92. Lea JS, Wenham RM, Sheets EE, Duska LR, Coleman RL, Miller DS, Schorge JO. Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival. NEAGO Annual Meeting, Stowe, VT, 6/2001.
93. Schorge JO, Wenham RM, Lea JS, Duska LR, Miller DS, Coleman RL, Muller CY, Sheets EE. Advanced cervical adenocarcinoma: Poor prognosis emphasizes the need for novel therapeutic approaches. 37th Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA (#2514), 5/2001.
94. Coleman RL, Lin W, Miller DS, King M, Farrar D, Muller CY, Schorge JO. Oral dexamethasone (DMS) attenuates doxil-induced palmar plantar erythema (PPE) in patients with recurrent gynecologic malignancies. 37th Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA (#883), 5/2001.
95. Muller CY, Coleman RL, Rogers P, Merritt JA, Parker K, Miller DS. Phase I intraperitoneal adenoviral p53 gene transfer in ovarian cancer. 37th Annual Meeting of the American Society of Clinical Oncology (ASCO), San Francisco, CA (#1025), 5/2001.
96. Schorge JO, Shelby KA, Robinson L, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Society of Gynecologic Oncologists (SGO) 32nd Annual Meeting, Nashville, TN, 3/2001.
97. Levenback C, Coleman RL, Burke TW, Delpassand ES, Lin WCM, Erdman WA, Johnston T. Lymphatic mapping and sentinel node identification in patients undergoing radical hysterectomy and pelvic lymphadenectomy. Society of Gynecologic Oncologists (SGO) 32nd Annual Meeting, Nashville, TN, 3/2001.
98. Lea JS, Sheets EE, Duska LR, Miller DS, Coleman RL, Muller CY, Schorge JO. The role of para-aortic lymph node dissection in early stage cervical adenocarcinoma. Society of Gynecologic Oncologists (SGO) 32nd Annual Meeting, Nashville, TN, 3/2001.
99. Levenback C, Coleman RL, Burke TW, Delpassand ES, Lin WM, Erdman W, Johnston T. Combined preoperative and intraoperative lymphatic mapping (IOLM) and sentinel node (SN) identification during radical hysterectomy (RH). 2nd International Sentinel Node Congress, Santa Monica, CA (#33), 12/2000.
100. Henderson NL, Coleman RL, Lin WM, Muller CY, Miller DS. Cervical conization to radical hysterectomy interval: does it matter? . 48th Annual Clinical Meeting, American College of Obstetricians and Gynecologists (ACOG), San Francisco, CA, 5/2000.
101. O'Boyle J, Lin W, Coleman R, Miller D, Farrar D, King M. Combined carboplatin (C) and weekly paclitaxel (P) chemotherapy for recurrent gynecologic malignancies: Preliminary data. 36th Annual Meeting American Society of Clinical Oncology (ASCO), New Orleans, LA (#1623D), 5/2000.
102. Lin WM, Ashfaq R, Coleman RL, Miller DS, Muller CY. Differential Expression of MIB-1, BCL-2 and FHIT in neuroendocrine tumors and squamous cell carcinomas of the uterine cervix. Western Association of Gynecologic Oncologists (WAGO) 29th Annual Meeting, Monterey, CA, 5/2000.
103. Coleman RL, Levenback C, Lin WM, Wolf JK, Burke TW, Bodurka-Bevers D, Wharton JT, Miller, DS. Feasibility of Combined intraoperative lymphatic mapping (IOLM) in patients with Early Cervical Cancer: A multi-institutional pilot study. Western Association of Gynecologic Oncologists (WAGO) 29th Annual Meeting, Monterey, CA, 5/2000.
104. Oh J, Barve M, Lin WM, Coleman RL, Santoso JT, Muller Cy, Ferrar D, King M, Lowe E, Miller DS. Treatment Outcomes and Prognostic Factors of Hydatidiform Moles. Western Association of Gynecologic Oncologists (WAGO) 29th Annual Meeting, Monterey, CA, 5/2000.
105. Hammerman RM, Lin WM, Michalopulos EA, Ashfaq R, Patel S, Coleman RL, Muller CY. Comparison of techniques for human papillomavirus detection in archival fluid-based cytology of cervical cancer and dysplasia. 4th Annual Meeting Society of Gynecologic Investigation, Chicago, IL (#836), 3/2000.
106. O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study. 31st Annual Meeting Society of Gynecologic Oncologists (SGO), San Diego, CA (#210), 2/2000.
107. Levenback C, Coleman RL, Burke T, Wolf J, Bodurka-Bevers D, Bevers M, Gershenson D. Intraoperative lymphatic mapping of the vulva with blue dye. 31st Annual Meeting Society of Gynecologic Oncologists (SGO), San Diego, CA (#18), 2/2000.
108. Muller CY, Coleman RL, Lin WM, Ashfaq R, Michalopulos J, Sherwood J, Abbatista M, Miller DS. P53 genetic polymorphism status as a biomarker for cervical dysplasia risk. 31st Annual Meeting Society of Gynecologic Oncologists (SGO), San Diego, CA (#61), 2/2000.
109. Day LN, Inman NN, O'Boyle JD, Coleman RL. Nutrition support in short bowel syndrome from multiple complications in a cervical cancer patient. A.S.P.E.N Clinical Congress, Nutrition Practice (#P76), 1/2000.

Book Chapters

1. Coleman RL, Gershenson DM. Ovarian Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Ed(s) MA Rodriquez, RS Walters, TW Burke. Springer: New York, 2013.
2. Coleman R, Sabbatini P. Targeted Therapy and Immunotherapy. In: Gynecologic Oncology, Clinical Practice & Surgical Atlas, 2012.
3. Moroney, John W and Coleman, Robert L. Novel Biologic and Cytotoxic Chemotherapies in Epithelial Ovarian Cancer. In: Textbook of Gynaecological Oncology. Ed(s) Ali Ayhan, Nicholas Reed, Murat Gultekin, Polat Dursun. Günes Publishing: Turkey, 780-789, 2011.
4. Matsuo K, Lu C, Shahzad MMK, Coleman RL, Sood AK. Role of pericytes in resistance to antiangiogenic therapy. In: The Tumor Microenvironment, 1st Edition. Ed(s) RG Bagley. Springer: New York, NY, 311-324, 2010. ISBN: 978-1-4419-6614-8.
5. Alpa M. Nick, Robert L. Coleman, and Anil K. Sood. Molecular therapeutics in epithelial ovarian cancer. In: Ovarian Cancer: State of the Art, 1. Ed(s) Robert C. Bast, Jr. and Maurie Markman. Remedica: London, UK, 109-160, 2009. ISBN: 978-1-905721-53-5.
6. Coleman RL, Moroney JW. Novel Biologic and Cytotoxic Chemotherapeutics in Epithelial Ovarian Cancer. In: Textbook in Gynaecologıcal Oncology. Ed(s) Ali Ayhan, Murat Gultekın, Polat Dursun. Gunes Publishing: Ankara, Turkey, 359-367, 2009. ISBN: 978-975-277-267-0.
7. Ramirez PT, Levenback C, Coleman RL. Laparoscopic Sentinel Lymph Node Identification in Cervical Cancer. In: Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy, Third. Ed(s) Camran Nezhat, Farr Nezhat, Ceana Nezhat. Cambridge University Press: New York, 447-452, 2008.
8. Han LY, Coleman RL. Ovarian Cancer Staging. In: Gynecologic Procedures for the General Surgeon, Operative Techniques in General Surgery. 9, Issue 2. Ed(s) Koltun WA. Elsevier: Philadelphia, 51-91, 2007.
9. Rao GG Coleman RL. Fallopian tube cancer. In: Gynecology & Obstetrics. JB Lippincott, 2004.
10. Herzog TJ, Kost ER, Coleman RL. Gynecology. In: Laparoscopic Surgery: Principles and Procedures. Marcel Dekker, Inc, 2004.
11. Coleman RL Coleman FK. Radiotherapy in vulvar carcinoma. In: Gynecology & Obstetrics. JB Lippincott, 2004.
12. Coleman RL, Munkarah A, Bristow RE. Secondary cytoreductive surgery. In print. In: Surgery for Ovarian Cancer: Principles and Practice. Parthenon Publishing Group Limited, 2004.
13. Coleman RL. Lymphatic mapping. In: An Atlas of Gynecologic Oncology. Taylor & Francis Books, Ltd, 2003.
14. Coleman RL. Secondary cytoreduction surgery for ovarian cancer. In Production. In: Principles and Practice. Parthenon Publishing, 2003.
15. Coleman RL. Anatomy and natural history of invasive female lower genital tract cancers (FLGTCs): Carcinomas of the cervix, vagina, and vulva. In: Atlas of Clinical Oncology. B.C. Decker Inc, 47-62, 2001.
16. Coleman RL Santoso JT. Vulvar carcinoma. In: Current Treatment Options in Oncology. 1(2). Current Science, Inc, 177-190, 2000.
17. Coleman RL Coleman FK. Radiotherapy in epithelial ovarian cancer. In: Gynecology & Obstetrics. 4:37. Williams & Wilkins/JB Lippincott, 1-15, 1999.
18. Coleman RL. Fallopian tube carcinoma. In: Gynecology & Obstetrics. 4:36. JB Lippincott, 1-90, 1998.
19. Hallum AV, Coleman RL, Wolf J. Gynecologic oncology. In: The M. D. Anderson Surgical Oncology Handbook. Little, Brown and Co, 326-368, 1995.
20. Coleman RL. The retroperitoneal mass. In: Management of Complications in Gynecologic Surgery. WB Saunders Company, 115-126, 1995.

Books (edited and written)

1. J. Richard Smith, Giuseppe del Priore, Robert L. Coleman, John Monaghan. An Atlas of Gynecologic Oncology: Investigation and Surgery, Third Edition, Third. Informa Healthcare, 2011. ISBN: ISBN: 9780415450591.
2. Lee P. Shulman, M.D. Ed(s) Lee P. Schulman, M.D. 2007 Year Book of Obstetrics, Gynecology, and Women's Health. In: 2007 Year Book Series. Elsevier: Philadelphia, PA, 2007.
3. Levenback, C, Coleman RL, Lu K, Sood AK. Ed(s) Levenback, C, Coleman RL, Lu K, Sood AK. Prognostic and Predictive Factors in Gynecologic Cancers, 1. Informa UK Ltd. London, 2007. ISBN: 0415391725.
4. Levenback C, Coleman R, Van der Zee AGJ. Clinical Lymphatic Mapping in Gynecologic Cancers. Martin Dunitz Ltd, 2004.
5. Santoso JT Coleman RL. Handbook of Gyn Oncology. McGraw-Hill, 2001.
6. Gershenson DM (ed) Coleman RL (guest ed). Operative Techniques in Gynecologic Surgery. WB Saunders Company, 2001.
7. Hallum AV, Coleman RL, Segreti E. Epithelial ovarian cancer. In: Study Guide for Textbook of Gynecology. WB Saunders Company, 1994.

Letters to the Editor

1. Levenback C, Coleman RL, Ansink A, van der Zee AG. Re: Terada et al. Sentinel node dissection and ultrastaging in squamous cell cancer of the vulva. Gynecol Oncol 76:40-44, 2000. Gynecol Oncol 77(3):484-5, 6/2000. PMID: 10831370.
2. Coleman RL. Correction to "Carboplatin and Short-Infusion Paclitaxel in High Risk and Advanced-Stage Ovarian Carcinoma". Cancer J Sci Am 3(5):314, 10/1997. PMID: 9334435.
3. Coleman RL. Prediction of residual neoplasia in hysterectomy specimens among women previously treated by cervical conization. Gynecol Oncol 66(2):336-7, 8/1997. PMID: 9264588.
4. Coleman RL. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 59:162-165, 1995.

Manuals, Teaching Aids, Other Teaching Publications

1. Coleman RL, Monk BJ. Gynecologic Oncology Update: Conversations with Oncology Investigators, Bridging the Gap between Research and Patient Care. Ed(s) N Love, 2015.
2. Ovarian Cancer Update: Conversations with Oncology Investigators (Faculty Interview). 3. Ed(s) Neil Love, MD. Research to Practice: Miami, Florida, 2/2011.
3. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper Ovarian Education Campaign [INTRODUCTORY PARAGRAPH-Herzog/Coleman] Project I-Background, Screening & Surveillance. 1, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20692025. e-Pub 8/7/2010. PMID: 20692025.
4. Coleman RL. Living Medical Textbook from Projects in Knowledge CME Activity - Oncology Women's Cancers Edition, Chapter 4 Recurrent Ovarian Cancer: State of the State. Projects in Knowledge: Little Falls, NJ, 01/19/2009 - 01/19/2010. e-Pub 1/2009.
5. Ovarian Cancer Update: Conversations with Oncology Investigators, Bridging the Gap between Research and Patient Care. 1, Issue 2. Ed(s) Neil Love, M.D. Research To Practice: Miami, FL, 6/2008.
6. Coleman RL, Herzog TJ. Ovarian and Cervical Cancer: Emerging Therapeutic Paradigms. Continuing Edge: USA, 22, 8/2007.
7. Current Trends in the Treatment of Ovarian Cancer CME Monograph, 2006.
8. Ramirez PT. Laparoscopic Surgical Simulation Curriculum, Surgical Research Program, First Edition. Ed(s) Collaborators: Robert Coleman, Charles Levenback. The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology: Houston, TX, 46, 12/2005.
9. Cases in Advanced Gynecologic Cancers: A Virtual Tumor Board Discussion. 2005.
10. Patterns of Practice in Selected Gynecologic Malignancies. 2005.
11. Platinum Compounds in the Treatment of Ovarian Cancer. 2005.
12. Clinical Insights CME CD. 2/2004.
13. Bowel Surgery Monograph. 2000.
14. Ovarian & Cervical Cancer Monograph. 2000.
15. Ovarian Cancer Monograph. 2000.
16. Recurrent Ovarian Cancer Monograph. 2000.
17. Women's Cancer Network. 2000.

Grant & Contract Support

Title: EphA2 Targeting in Uterine Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2010 - 2/28/2014

Last updated: 4/6/2016